Generex Biotechnology (GNBTQ) 10-K 26 Oct 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jul. 31, 2017	Sep. 29, 2017
Document And Entity Information
Entity Registrant Name	GENEREX BIOTECHNOLOGY CORP
Entity Central Index Key	1,059,784
Document Type	10-K
Document Period End Date	Jul. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float	$ 5,300,000
Entity Common Stock, Shares Outstanding		1,065,093
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Current Assets:
Cash and cash equivalents	$ 2,879,165	$ 16,899
Inventory, net	10,035
Other current assets	21,891	8,077
Total Current Assets	2,911,091	24,976
Property and equipment (Note 3)	573	1,298
Call option (Note 14)	4,237,829
Intangible asset (Note 14)	2,911,377
Patents, net (Note 4)	25,851
Other assets, net	7,824
TOTAL ASSETS	10,094,545	26,274
Current Liabilities:
Accounts payable and accrued expenses	10,172,610	8,950,870
Loans from related parties (Note 6)	13,738,140
Loan payable (Note 7)		50,000
Total Current Liabilities	23,910,750	9,000,870
Derivative warrant liability (Note 11 and 12)		2,048,846
Derivative additional investment rights liability (Note 11 and 12 and 14)		193,408
Warrants to be issued (Note 14)	66,060,026
Total Liabilities	89,970,776	11,243,124
Stockholders' Deficiency (Note 11):
Common stock, $.001 par value; authorized 2,450,000 and 2,450,000 shares at July 31, 2017 and July 31, 2016, respectively; 1,068,101 and 908,541 issued and outstanding at July 31, 2017 and July 31, 2016, respectively	1,068	909
Common stock payable	2,168,951
Additional paid-in capital	368,409,627	363,687,741
Accumulated deficit	(445,720,566)	(375,704,372)
Accumulated other comprehensive income	783,150	798,872
Non-controlling interest	(5,518,465)
Total Stockholders' Deficiency	(79,876,231)	(11,216,850)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	10,094,545	26,274
Series F Convertible Preferred Stock
Stockholders' Deficiency (Note 11):
9% Convertible Preferred Stock
Series G Convertible Preferred Stock
Stockholders' Deficiency (Note 11):
9% Convertible Preferred Stock
Series H Convertible Preferred Stock
Stockholders' Deficiency (Note 11):
9% Convertible Preferred Stock	3
Series I Convertible Preferred Stock
Stockholders' Deficiency (Note 11):
9% Convertible Preferred Stock	$ 1

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jul. 31, 2017	Jul. 31, 2016
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,450,000	2,450,000
Common stock, shares issued	1,068,101	908,541
Common stock, shares outstanding	1,068,101	908,541
Series F Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Convertible preferred stock, shares authorized	4,150	4,150
Convertible preferred stock, shares issued	0	120
Convertible preferred stock, shares outstanding	0	120
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series G Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Convertible preferred stock, shares authorized	1,000	1,000
Convertible preferred stock, shares issued	0	500
Convertible preferred stock, shares outstanding	0	500
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series H Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$ 1,000	$ 0.001
Convertible preferred stock, shares authorized	109,000	109,000
Convertible preferred stock, shares issued	3,000	0
Convertible preferred stock, shares outstanding	3,000	0
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%
Series I Convertible Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	6,000	6,000
Convertible preferred stock, shares issued	790	0
Convertible preferred stock, shares outstanding	790	0
Convertible preferred stock, cumulative percentage of interest	9.00%	9.00%

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Operating Expenses:
Research and development	$ 422,294	$ 467,382
General and administrative	1,174,547	1,435,186
Total Operating Expenses	1,596,841	1,902,568
Operating Loss	(1,596,841)	(1,902,568)
Other Income/(Expense):
Impairment of patents (Note 4)		1,165,864
Interest expense	(743,101)	(418,500)
Changes in fair value of contingent purchase consideration (Note 14)	(61,822,197)
Impairment of goodwill (Note 14)	(13,380,377)
Change in fair value of derivative liabilities	709,917	263,823
Net (Loss)	(76,832,599)	(3,223,109)
Net (loss) attributable to noncontrolling interests	(6,816,405)
Net (Loss) Available to Common Stockholders	$ (70,016,194)	$ (3,223,109)
Net (Loss) Per Common Share (Note 10) - Basic	$ (70.92)	$ (3.69)
Net (Loss) Per Common Share (Note 10) - Diluted	$ (70.92)	$ (3.69)
Shares Used to Compute (Loss) per Share (Note 10) - basic and diluted	987,288	873,309
Other Comprehensive Income
Net (Loss)	$ (70,016,194)	$ (3,223,109)
Change in foreign currency translation adjustments	(15,722)	(9,865)
Comprehensive Loss Available to Common Stockholders	$ (70,031,916)	$ (3,232,974)

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIENCY - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Preferred Stock
Balance
Balance (in shares)	620	1,170
Issuance of common stock in exchange for services
Issuance of common stock in exchange for services (in shares)
Issuance of common stock upon conversion of preferred stock
Issuance of common stock upon conversion of preferred stock (in shares)	(620)	(550)
Issuance of common stock for preferred stock make whole payments
Issuance of common stock for preferred stock make whole payments (in shares)
Exercise of stock options/warrants for cash
Exercise of stock options/warrants for cash (in shares)
Cashless exercise of warrants
Cashless exercise of warrants (in shares)
Issuance of stock options for compensation liabilities
Issuance of stock options as compensation
Issuance of common stock and warrants for acquisition
Issuance of common stock and warrants for acquisition (shares)
Issuance of series H preferred stock for cash	$ 3
Issuance of series H preferred stock for cash (in shares)	3,000
Issuance of series I preferred stock for conversion of debt	$ 1
Issuance of series I preferred stock for conversion of debt (in shares)	790
True-up rounding shares for reverse stock split
True-up rounding shares for reverse stock split (in shares)
Noncontrolling interest
Net loss
Currency translation adjustment
Balance	$ 4
Balance (in shares)	3,790	620
Common Stock
Balance	$ 909	$ 826
Balance (in shares)	908,541	825,496
Issuance of common stock in exchange for services
Issuance of common stock in exchange for services (in shares)		3,000
Issuance of common stock upon conversion of preferred stock	$ 41	$ 37
Issuance of common stock upon conversion of preferred stock (in shares)	41,333	36,667
Issuance of common stock for preferred stock make whole payments	20	20
Issuance of common stock for preferred stock make whole payments (in shares)	19,529	20,139
Exercise of stock options/warrants for cash	$ 3	$ 26
Exercise of stock options/warrants for cash (in shares)	3,333	25,939
Cashless exercise of warrants	$ 31
Cashless exercise of warrants (in shares)	31,195
Issuance of stock options for compensation liabilities
Issuance of stock options as compensation
Issuance of common stock and warrants for acquisition	$ 53
Issuance of common stock and warrants for acquisition (shares)	53,211
Issuance of series H preferred stock for cash
Issuance of series H preferred stock for cash (in shares)
Issuance of series I preferred stock for conversion of debt
Issuance of series I preferred stock for conversion of debt (in shares)
True-up rounding shares for reverse stock split	$ 11
True-up rounding shares for reverse stock split (in shares)	10,958
Noncontrolling interest
Net loss
Currency translation adjustment
Balance	$ 1,068	$ 909
Balance (in shares)	1,068,100	908,541
Common Stock Payable
Balance
Issuance of common stock in exchange for services
Issuance of common stock upon conversion of preferred stock
Issuance of common stock for preferred stock make whole payments
Exercise of stock options/warrants for cash
Cashless exercise of warrants	1,071,851
Issuance of stock options for compensation liabilities
Issuance of stock options as compensation
Issuance of common stock and warrants for acquisition	1,097,100
Issuance of series H preferred stock for cash
Issuance of series I preferred stock for conversion of debt
True-up rounding shares for reverse stock split
Noncontrolling interest
Net loss
Currency translation adjustment
Balance	2,168,951
Additional Paid-In Capital
Balance	363,687,741	363,381,380
Issuance of common stock in exchange for services		4,500
Issuance of common stock upon conversion of preferred stock	$ (41)	$ (37)
Issuance of common stock for preferred stock make whole payments	167,380	148,480
Exercise of stock options/warrants for cash	$ 49,997	$ (26)
Cashless exercise of warrants	460,455
Issuance of stock options for compensation liabilities		123,147
Issuance of stock options as compensation		30,297
Issuance of common stock and warrants for acquisition	253,763
Issuance of series H preferred stock for cash	2,999,997
Issuance of series I preferred stock for conversion of debt	790,346
True-up rounding shares for reverse stock split	(11)
Noncontrolling interest
Net loss
Currency translation adjustment
Balance	368,409,627	363,687,741
Accumulated Deficit
Balance	(375,704,372)	(372,481,263)
Issuance of common stock in exchange for services
Issuance of common stock upon conversion of preferred stock
Issuance of common stock for preferred stock make whole payments
Exercise of stock options/warrants for cash
Cashless exercise of warrants
Issuance of stock options for compensation liabilities
Issuance of stock options as compensation
Issuance of common stock and warrants for acquisition
Issuance of series H preferred stock for cash
Issuance of series I preferred stock for conversion of debt
True-up rounding shares for reverse stock split
Noncontrolling interest
Net loss	(70,016,194)	(3,223,109)
Currency translation adjustment
Balance	(445,720,566)	(375,704,372)
Accumulated Other Comprehensive Income
Balance	798,872	808,737
Issuance of common stock in exchange for services
Issuance of common stock upon conversion of preferred stock
Issuance of common stock for preferred stock make whole payments
Exercise of stock options/warrants for cash
Cashless exercise of warrants
Issuance of stock options for compensation liabilities
Issuance of stock options as compensation
Issuance of common stock and warrants for acquisition
Issuance of series H preferred stock for cash
Issuance of series I preferred stock for conversion of debt
True-up rounding shares for reverse stock split
Noncontrolling interest
Net loss
Currency translation adjustment	(15,722)	(9,865)
Balance	783,150	798,872
Sub Total
Balance	(11,216,850)	(8,290,320)
Issuance of common stock in exchange for services		4,500
Issuance of common stock upon conversion of preferred stock
Issuance of common stock for preferred stock make whole payments	167,400	148,500
Exercise of stock options/warrants for cash	$ 50,000
Cashless exercise of warrants	1,532,337
Issuance of stock options for compensation liabilities		123,147
Issuance of stock options as compensation		30,297
Issuance of common stock and warrants for acquisition	1,350,916
Issuance of series H preferred stock for cash	3,000,000
Issuance of series I preferred stock for conversion of debt	790,347
True-up rounding shares for reverse stock split
Noncontrolling interest
Net loss	(70,016,194)	(3,223,109)
Currency translation adjustment	(15,722)	(9,865)
Balance	(74,357,766)	(11,216,850)
Noncontrolling Interest
Balance
Issuance of common stock in exchange for services
Issuance of common stock upon conversion of preferred stock
Issuance of common stock for preferred stock make whole payments
Exercise of stock options/warrants for cash
Cashless exercise of warrants
Issuance of stock options for compensation liabilities
Issuance of stock options as compensation
Issuance of common stock and warrants for acquisition
Issuance of series H preferred stock for cash
Issuance of series I preferred stock for conversion of debt
True-up rounding shares for reverse stock split
Noncontrolling interest	1,297,940
Net loss	(6,816,405)
Currency translation adjustment
Balance	(5,518,465)
Balance	(11,216,850)	(8,290,320)
Issuance of common stock in exchange for services		4,500
Issuance of common stock upon conversion of preferred stock
Issuance of common stock for preferred stock make whole payments	167,400	148,500
Exercise of stock options/warrants for cash	$ 50,000
Cashless exercise of warrants	1,532,337
Issuance of stock options for compensation liabilities		123,147
Issuance of stock options as compensation		30,297
Issuance of common stock and warrants for acquisition	1,350,916
Issuance of series H preferred stock for cash	3,000,000
Issuance of series I preferred stock for conversion of debt	790,347
True-up rounding shares for reverse stock split
Noncontrolling interest	1,297,940
Net loss	(76,832,599)	(3,223,109)
Currency translation adjustment	(15,722)	(9,865)
Balance	$ (79,876,231)	$ (11,216,850)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Cash Flows From Operating Activities:
Net (loss)	$ (76,832,599)	$ (3,223,109)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,045	265,210
Common stock issued for services rendered		4,500
Write-off of patents		1,165,864
Issuance of stock options as compensation		27,344
Common stock issued for interest on convertible debentures and preferred stock		148,500
Loss on goodwill impairment	13,380,377
Changes in fair value of contingent purchase consideration	61,822,197
Loss on disposal of property and equipment	1,276
Amortization of debt discount	252,700
Forgiveness of debt from related party	(83,554)
Change in fair value of derivative liabilities	(709,917)	(263,823)
Changes in operating assets and liabilities
Accounts receivable	980
Inventory	11,106
Accounts payable and accrued expenses	899,750	1,056,955
Other current assets	77,660	43,076
Other assets	4,630
Net Cash Used in Operating Activities	(1,170,349)	(775,483)
Cash Flows From Investing Activities:
Deposit on investment	(4,000,000)
Return of investment	4,000,000
Cash received in acquisition of a business	12,363
Net cash (used) in investing activities	12,363
Cash Flows From Financing Activities:
Loan proceeds from related party	1,171,021
Repayment of loan to related party	(14,096)
Proceeds from issuance of long-term debt		50,000
Proceeds from convertible note payable	503,879
Repayment of convertible note payable	(674,855)
Proceeds from exercise of stock options		2,952
Proceeds from issuance of preferred stock	3,000,000
Proceeds from exercise of warrants	50,000
Net Cash Provided by Financing Activities	4,035,949	52,952
Effects of currency translation on cash and cash equivalents	(15,698)	(10,535)
Net Increase (Decrease) in Cash and Cash Equivalents	2,862,266	(733,066)
Cash and Cash Equivalents, Beginning of Period	16,899	749,965
Cash and Cash Equivalents, End of Period	2,879,165	16,899
Supplemental Disclosure of Cash Flow Information
Payment of note by issuance of convertible note payable	50,000
Issuance of stock options to satisfy compensation liabilities		123,147
Cashless exercise of warrants	1,532,337
Conversion of debt from related party	790,347
Common stock issued for make whole payments	167,400
Issuance of round up shares	$ 11
Shares issued for acquisition of a business	1,350,916
Series F Convertible Preferred Stock
Supplemental Disclosure of Cash Flow Information
Conversion of convertible preferred stock to common stock	$ 8
Series G Convertible Preferred Stock
Supplemental Disclosure of Cash Flow Information
Conversion of convertible preferred stock to common stock	$ 33

Organization and Business

Organization and Business	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Organization and Business	Note 1 –Organization of Business and Going Concern: Generex Biotechnology Corporation (“Generex” or the “Company”), was formed in the State of Delaware on September 4, 1997 and its year-end is July 31. It is engaged primarily in the research and development of drug delivery systems and the use of the Company’s proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator; and through the Company’s wholly-owned subsidiary, Antigen Express, Inc. (“Antigen”), has undertaken work on immunomedicines incorporating proprietary vaccine formulations. On January 18, 2017, the Company closed an Acquisition Agreement pursuant to which the Company acquired a 51% interest in Hema Diagnostic Systems, LLC (“HDS”), a Florida limited liability company established in December 2000 to market and distribute rapid test devices including infectious diseases. Since 2002, HDS has been developing an expanding line of rapid diagnostic tests (RDTs) including such diseases as Human Immunodeficiency Virus (HIV) – 1/2, tuberculosis, malaria, hepatitis, syphilis, typhoid and dengue as well as other infectious diseases. On March 14, 2017, the Company effected a one-for-one thousand (1:1,000) reverse stock split whereby the Company (i) decreased the number of authorized shares of Common Stock by a ratio equal to one-for-one thousand (1:1,000) (the “Reverse Split Ratio”), and (ii) correspondingly and proportionately decreased, by a ratio equal to the Reverse Split Ratio, the number of issued and outstanding shares of Common Stock (the “Reverse Stock Split”). Proportional adjustments for the reverse stock split were made to the Company's outstanding stock options, warrants and equity incentive plans for all periods presented. Going Concern The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. The Company has experienced negative cash flows from operations since inception and has an accumulated deficit of approximately $446 million and a working capital deficiency of approximately $21 million at July 31, 2017. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to implement its new investment acquisition plans. Management’s plans in order to meet its operating cash flow requirements include financing activities such as private placements of its common stock, preferred stock offerings, and issuances of debt and convertible debt instruments. Management is also actively pursuing financial and strategic alternatives, including strategic investments and divestitures, industry collaboration activities and strategic partners. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the balance sheet date. There are no assurances that such additional funding will be achieved and that the Company will succeed in its future operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s inability to obtain required funding in the near future or its inability to obtain funding on favorable terms will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially and adversely affected, and the Company may have to cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies: Principles of Consolidation The consolidated financial statements include the accounts of the Company and all of its wholly-owned and majority-owned subsidiaries. All significant intercompany transactions and balances have been eliminated. The subsidiaries included in the Company’s consolidated financial statements are: Generex Pharmaceuticals, Inc.; Generex (Bermuda), Inc.; Antigen Express, Inc.; 1097346 Ontario, Inc.; Hema Diagnostics Systems, LLC; Hema Diagnostics Systems Panama S.A.; Rapid Medical Diagnostics Corporation. Provided, however, that in the event that the Purchasers fail to purchase 100% of the shares of Preferred Stock at any given Closing (other than the Closing Series H Tranche One) notwithstanding that the Company is ready, willing, and able to effect such Closing in accordance with the terms and conditions of this Agreement (a “Failure to Purchase Event”), then: (i) the Purchasers’ entitlement to purchase any Preferred Stock in respect of that Closing and any and all subsequent Closings under this Agreement is forfeit in total, (ii) the Company shall have no obligation to issue any further Securities to the Purchasers under this Agreement, and (iii) the Company shall have no recourse against the Purchasers, at law or in equity, in respect of such Failure to Purchase Event. For greater certainty, any securities that would otherwise have been issuable by the Company to the Purchasers but for the Failure to Purchase Event shall not be Securities (as that term is defined in this Agreement) and the Company shall have no registration obligation in respect thereof under the Registration Rights Agreement. Business Combinations Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any non-controlling interest, over the fair value of the identifiable net assets acquired. Cash and Cash Equivalents The Company considers Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the Weighted Average method. The Company periodically evaluates its inventory for any obsolete or slow moving items based on production lot number and advances in production design or technology. Any inventory determined to be obsolete or slow moving inventory is written down to its net realizable value. Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on the straight-line method over the estimated useful lives of the assets, which range from three to seven years. Gains and losses on depreciable assets retired or sold are recognized in the consolidated statement of operations and comprehensive loss in the year of disposal. Repairs and maintenance expenditures are expensed as incurred. Patents Capitalized patent costs represent legal costs incurred to establish patents and a portion of the acquisition price paid attributed to patents upon the acquisition of Antigen in August 2003 and the acquisition of HDS in January 2017. When patents reach a mature stage, any associated legal costs are comprised mostly of maintenance fees and costs of national applications and are expensed as incurred. Capitalized patent costs are amortized on a straight line basis over the remaining life of the patent. As patents are abandoned, the net book value of the patent is written off. In-process Research & Development: The costs of in-process research and development (“IPR&D”), related to the Company’s business combination with HDS, were recorded at fair value on the acquisition date. IPR&D intangible assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. The Company assesses the impairment of long-lived assets under FASB ASC Topic 360 whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable and exceeds its fair value. The carrying amount of the long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset. Derivative Warrant Liability The Company’s derivative warrant instruments are measured at fair value using the binomial valuation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the warrant. The liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss under the caption “Change in fair value of derivative liabilities.” Research and Development Costs Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of experimental drugs, including payroll costs, and amounts incurred for conducting clinical trials. Amounts expected to be received from governments under research and development tax credit arrangements are offset against current research and development expense. Income Taxes Income taxes are accounted for under the asset and liability method prescribed by FASB ASC Topic 740. These standards require a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more likely than not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. At The Company adopted the FASB guidance concerning accounting for uncertainty in income taxes, which clarifies the accounting and disclosure for uncertainty in tax positions, as of August 1, 2007. The guidance requires that the Company determine whether it is more likely than not that a tax position will not be sustained upon examination by the appropriate taxing authority. If a tax position does not meet the more likely than not recognition criterion, the guidance requires that the tax position be measured at the largest amount of benefit greater than 50 percent not likely of being sustained upon ultimate settlement. Based on the Company’s evaluation, management has concluded that there are no significant uncertain tax positions requiring recognition in the consolidated financial statements. Stock-Based Compensation The Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable. The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments issued to consultants and other non-employees. Net Loss per Common Share Basic earnings per share is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted earnings per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings. Comprehensive Income/(Loss) Other comprehensive income/(loss), which includes only foreign currency translation adjustments, is shown in the consolidated statements of operations and comprehensive loss and in the consolidated statements of changes in stockholders’ deficiency. Foreign Currency Translation The functional and reporting currency of the Company and most of its subsidiaries is the United States Dollar. One subsidiary, Generex Pharmaceuticals, Inc., has a functional currency of the Canadian Dollar. Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at an average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary’s financial statements from its functional currency to the Company’s functional currency are recorded in the other comprehensive loss component of stockholders’ equity. Gains and losses resulting from foreign currency transactions are included in the statement of operations and comprehensive loss. Fair Value of Financial Instruments Fair value is defined under FASB ASC Topic 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for an asset or liability in an orderly transaction between participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The levels are as follows: • Level 1 - Quoted prices in active markets for identical assets or liabilities • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses, call option, warrants to be issued, derivative warrant liability, derivative additional investment right liability, loans payable and loans from related parties. All of these items, except of the call option, derivative warrant liability, derivative additional investment right liability and warrants to be issued, were determined to be Level 1 fair value measurements. The carrying amounts of cash and cash equivalents, other current assets, accounts payable and accrued expenses and the loans from related parties approximate their respective fair values because of the short maturities of these instruments. The call option, derivative warrant liability, derivative additional investment right liability and warrants to be issued, were determined to be Level 2 fair value measurements. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company evaluates its estimates, including those related to long lived assets (including patents) impairment valuations, derivatives and contingencies and litigation, on an ongoing basis. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Critical accounting estimates are reviewed and discussed with the Board of Directors. The Company considers an accounting estimate to be critical if it requires assumptions to be made that were uncertain at the time the estimate was made, if changes in the estimate or if different estimates that could have been selected would have a material impact on our results of operations or financial condition. Effects of Recent Accounting Pronouncements: Recently Issued Accounting Pronouncements We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effective dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15 and does not expect any material impact on the Company’s consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment

Property and Equipment

Property and Equipment	12 Months Ended
	Jul. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 3 - Property and Equipment July 31, 2017 2016 Equipment $ 82,602 $ — Leasehold Improvements 40,445 — Furniture and Fixtures 1,402 10,900 Less: Accumulated depreciation 123,876 9,602 Property and Equipment, net $ 573 $ 1,298 Depreciation expense related to property and equipment amounted to $3,675 and $1,517 for the years ended July 31, 2017 and 2016, respectively.

Patents

Patents	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Patents	Note 4 - Patents The costs and accumulated amortization of patents are summarized as follows: Beginning balance as of August 1, 2015 $ 1,430,016 Additions 17,742 Less: Amortization expense 281,894 Write-off due to abandonment (1,165,864 ) Patents, net as of July 31, 2016 — Net patents acquired during acquisition of HDS 27,221 Less: Amortization expense 1,370 Patents, net as of July 31, 2017 $ 25,851 Weighted average life 9 years Amortization expense amounted to $1,370 and $281,894 for the years ended July 31, 2017 and 2016, respectively. During the year ended July 31, 2016, the Company wrote off patents with a net book value of $1,165,864 as the patents had been abandoned or were no longer being used.

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 5 - Income Taxes The Company has incurred losses since inception, which have generated net operating loss (“NOL”) carryforwards. The NOL carryforwards arise from both United States and Canadian sources. Pre-tax (losses) arising from domestic operations (United States) were $(76,823,599) and $(1,374,725) for the years ended July 31, 2017 and 2016, respectively. Pre-tax (losses) arising from foreign operations (Canada) were $(869,116) and $(504,101) for the years ended July 31, 2017 and 2016, respectively. As of July 31, 2016, the Company has NOL carryforwards in Generex Biotechnology Corporation of approximately $200 million, which expire in 2018 through 2036, in Generex Pharmaceuticals Inc. of approximately $34.7 million, which expire in 2018 through 2036, and in Antigen Express, Inc. of approximately $31.3 million, which expire in 2018 through 2036. These loss carryforwards are subject to limitation due to the acquisition of Antigen and may be limited in future years due to certain structural ownership changes which have occurred over the last several years related to the Company’s equity and convertible debenture financing transactions. For the years ended July 31, 2017 and 2016, the Company’s effective tax rate differs from the federal statutory rate principally due to net operating losses and other temporary differences for which no benefit was recorded. Deferred income taxes consist of the following: July 31, 2017 2016 Net operating loss carryforwards $ 88,428,273 $ 86,895,338 Other temporary differences 4,132,264 150,004 Intangible assets — — Total Deferred Tax Assets 92,560,537 87,045,342 Valuation Allowance (92,560,537 ) (86,678,987 ) Deferred Tax Liabilities Intangible assets (- ) (366,355 ) Other temporary differences — — Total Deferred Tax Liabilities — — Net Deferred Income Taxes $ — $ — A reconciliation of the United States Federal Statutory rate to the Company’s effective tax rate for the years ended July 31, 2017 and 2016 is as follows: July 31, 2017 2016 Federal statutory rate (34.0 )% (34.0 )% Increase (decrease) in income taxes resulting from: Imputed interest income on intercompany receivables from foreign subsidiaries 0 4 Non-deductible or non-taxable items 27 (3 ) Other temporary differences (1 ) 26 Change in valuation allowance 8 7 Effective tax rate — % — % As of July 31, 2017, the Company had no tax benefits which have not been fully allowed for, and no adjustment to its financial position, results of operations or cash flows was required. The Company does not expect that unrecognized tax benefits will increase within the next twelve months. The Company records interest and penalties related to tax matters within other expense on the accompanying consolidated statement of operations. These amounts are not material to the consolidated financial statements for the periods presented. Generally, tax years 2014 to 2017 remain open to examination by the Internal Revenue Agency or other tax jurisdictions to which the Company is subject. The Company’s Canadian tax returns are subject to examination by federal and provincial taxing authorities in Canada. Generally, tax years 2009 to 2017 remain open to examination by the Canada Revenue Agency or other tax jurisdictions to which the Company is subject.

Loans from Related Parties

Loans from Related Parties	12 Months Ended
	Jul. 31, 2017
Summary of Investments, Other than Investments in Related Parties [Abstract]
Loan from Related Party	Note 6 - Loans from Related Parties On January 16, 2017, Joseph Moscato, Chief Executive Officer and director (“Moscato”), and Lawrence Salvo, Senior Vice President and director (“Salvo”), each made an unsecured $250,000, non-interest bearing, advances to the Company, $500,000 in the aggregate, which the Company paid to Emmaus Life Sciences, Inc. pursuant to the Emmaus Letter of Intent (“Emmaus LOI”) (see Note 9). Both Moscato and Salvo made other advances ($75,820 and $82,803, respectively) to permit the Company to pay certain third party expenses in connection with the implementation of the Company’s repurposed business plan, including legal, accounting, transfer agent, Edgarization, and press release fees. On April 27, 2017, the Company converted 100% of such advances, $658,622 in the aggregate (the “Moscato – Salvo Advances”) into 790 shares of Series I preferred stock (see Note 11). HDS received substantially all of its funding from a shareholder, who owned 98.9% of HDS prior to the acquisition of HDS by the Company. The loan is unsecured, matures on December 31, 2019 and accrued interest at 0.75% per annum through January 19, 2017, and bearing no interest thereafter. Upon acquisition of HDS by the Company (see Note 14), the outstanding principal balance was $13,239,837 and total accrued interest of $191,869. This loan is subject to a call option (Note 14) which, if exercised, the principal and accrued interest through January 18, 2017 would be eliminated. From January 19, 2017 through July 31, 2017, the loan principal increased by $498,303. As of July 31, 2017, the outstanding principal balance was $13,738,140.

Loan Payable

Loan Payable	12 Months Ended
	Jul. 31, 2017
Notes to Financial Statements
Loan Payable	Note 7 – Loan Payable In May 2016, the Company borrowed $50,000 from a lender (“Demand Note”). This unsecured note bore interest at 9% per annum and was due on demand In March 2017, this note was cancelled upon issuance of a new convertible note payable (See Note 8).

Convertible Note Payable

Convertible Note Payable	12 Months Ended
	Jul. 31, 2017
Notes to Financial Statements
Convertible Note Payable	Note 8 – Convertible Note Payable On March 6, 2017, Generex entered into a Securities Purchase Agreement with Alpha Capital Anstalt (“Alpha”), pursuant to which the Company agreed to issue a Convertible Note due March 6, 2018 (“Convertible Note”) in the principal amount of $674,855. This Convertible Note bore no interest, except in the event of a default, in which the default interest rate was 15% per annum. Consideration received for the Convertible Note was $562,379, comprised of $500,000 in cash (paid directly to Emmaus Life Sciences, Inc. pursuant to the Emmaus LOI (see Note 9)), the cancellation of a $50,000 Demand Note the Company had issued to the investor in May 2016 (See Note 7), $3,879 in accrued interest on the Demand Note and $8,500 in legal fees for the investor’s counsel, which the Company was obligated to pay pursuant to the Securities Purchase Agreement. This Convertible Note was convertible, at the option of the holder, at any time, into shares of common stock at a conversion rate of $10.00 per share. Upon issuance, the Company recorded a debt discount of $120,976, consisting of $112,476 original issue discount and $8,500 of legal fees, to be amortized over the term of the Convertible Note. The Convertible Note included a provision stating that if the Company failed to timely consummate the transaction with Emmaus Life Sciences, Inc. pursuant to the Letter of Intent, the Note would become immediately due and payable, On May 30, 2017, the Company received notice from the investor’s counsel declaring the Note due and payable due to the termination of the Letter of Intent. In July 2017, the principal balance of the Convertible Note was fully repaid. In addition, the Company agreed to pay a late fee of $75,000 to Alpha, of which $27,000 remains due as of July 31, 2017 and is included in accounts payable and accrued expenses. For the year ended July 31, 2017, amortization of debt discount was $120,976 utilizing effective interest rate of 19.91%.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 - Commitments and Contingencies: Emmaus LOI On January 16, 2017, the Company and Emmaus Life Sciences, Inc. (“Emmaus”) entered into a letter of intent (“LOI”) contemplating that the Company will acquire a controlling interest in the outstanding capital stock of Emmaus for a total consideration of $225,000,000 in cash and Generex stock. The purchase price for shares of stock of the Emmaus Shares will consist of $10,000,000 in cash and $215,000,000 worth of shares of the Company’s common stock (“Company Shares”). The Company paid an aggregate $4,000,000 in cash deposits to Emmaus under the LOI. On May 16, 2017, the LOI was terminated and Emmaus repaid the $4,000,000. Pending Litigation In February 2001, a former business associate of the former Vice President of Research and Development (“VP”) of the Company and an entity known as Centrum Technologies Inc. (“CTI”) commenced an action in the Ontario Superior Court of Justice against the Company and the VP seeking, among other things, damages for alleged breaches of contract and tortious acts related to a business relationship between this former associate and the VP that ceased in July 1996. The plaintiffs’ statement of claim also seeks to enjoin the use, if any, by the Company of three patents allegedly owned by CTI. The three patents are entitled Liquid Formulations for Proteinic Pharmaceuticals Vaccine Delivery System for Immunization, Using Biodegradable Polymer Microspheres Controlled Releases of Drugs or Hormones in Biodegradable Polymer Microspheres On May 20, 2011, Rose Perri, a former officer of the Company, filed a statement of claim (subsequently amended) in the Ontario Superior Court of Justice, naming as defendants the Company and certain directors of the Company, John Barratt, Brian Masterson, Mark McGee, and Mr. Fletcher. In this action, Ms. Perri has alleged that defendants engaged in discrimination, harassment, bad faith and infliction of mental distress in connection with the termination of her employment with the Company. Ms. Perri is seeking damages in this action in excess of $7,000,000 for, among other things, breach of contract, breach of fiduciary duty, violations of the Ontario Human Rights Code and aggravated and punitive damages. On September 20, 2011, the defendants filed a statement of defense and counterclaim, also naming Time Release Corp., Khazak Group Consulting Corp., and David Khazak, C.A. as defendants by counterclaim, and seeking damages of approximately $2.3 million in funds that the defendants allege Ms. Perri wrongly caused the Company to pay to third parties in varying amounts over several years and an accounting of certain third-party payments, plus interests and costs. The factual basis for the counterclaim involves payments made by the Company to third parties believed to be related to Ms. Perri. The Company intends to defend this action and pursue its counterclaim vigorously and is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding. On June 1, 2011, Golden Bull Estates Ltd. filed a claim (subsequently amended) in the Ontario Superior Court of Justice, naming the Company, 1097346 Ontario, Inc. and Generex Pharmaceuticals, Inc. as defendants. The plaintiff, Golden Bull Estates Ltd., is controlled by Ms. Perri. The plaintiff alleges damages in the amount of $550,000 for breach of contract, $50,000 for punitive damages, plus interest and costs. The plaintiff’s claims relate to an alleged contract between the plaintiff and the Company for property management services for certain Ontario properties owned by the Company. The Company terminated the plaintiff’s property management services in April 2011. Following the close of pleadings, the Company served a motion for summary judgment. The plaintiff responded by amending its statement of claim to include a claim to the Company’s interest in certain of its real estate holdings. The plaintiff moved for leave to issue and register a Certificate of Pending Litigation in respect of this real estate. The motion was not successful in respect of any current real estate holdings of the Company. The Company is not able to predict the ultimate outcome of this legal proceeding at the present time or to estimate an amount or range of potential loss, if any, from this legal proceeding. In December 2011, a vendor of the Company commenced an action against the Company and its subsidiary, Generex Pharmaceuticals, Inc., in the Ontario Superior Court of Justice claiming damages for unpaid invoices including interest in the amount of $429,000, in addition to costs and further interest. The Company responded to this statement of claim and also asserted a counterclaim in the proceeding for $200,000 arising from the vendor’s breach of contract and detinue, together with interest and costs. On November 16, 2012, the parties agreed to settle this action and the Company has agreed to pay the plaintiff $125,000, following the spinout of its subsidiary Antigen, from the proceeds of any public or private financing related to Antigen subsequent to such spinout. Each party agreed to execute mutual releases to the claim and counterclaim to be held in trust by each party’s counsel until payment of the settlement amount. Following payment to the plaintiff, the parties agree that a Consent Dismissal Order without costs will be filed with the court. If the Company fails to make the payment following completion of any post-spinout financing related to Antigen or any other subsidiaries, the Plaintiffs may take out a judgment in the amount of the claim plus interest of 3% per annum and costs fixed at $25,000. On August 22, 2017, Generex received a letter from counsel for Three Brothers Trading LLC, d/b/a Alternative Execution Group (“AEXG”), claiming breach of a Memorandum of Understanding (“MOU”) between Generex and AEXG. The MOU related to AEXG referring potential financing candidate to Generex. The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing from Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs. Generex management believes the Pharma Trials, LLC Financing was not subject to the prohibitions because the representative of Pharma Trials, LLC was a director of Generex, and for other reasons. The Company is involved in certain other legal proceedings in addition to those specifically described herein. Subject to the uncertainty inherent in all litigation, the Company does not believe at the present time that the resolution of any of these legal proceedings is likely to have a material adverse effect on the Company’s consolidated financial position, operations or cash flows. With respect to all litigation, as additional information concerning the estimates used by the Company becomes known, the Company reassesses its position both with respect to accrued liabilities and other potential exposures.

Net (Loss) _ Income Per Share (

Net (Loss) / Income Per Share (“EPS”)	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Net Income (Loss) Per Share (EPS)	Note 10 - Net (Loss) / Income Per Share (“EPS”): Basic EPS and diluted EPS for the years ended July 31, 2017 and 2016 have been computed by dividing the net loss available to common stockholders for the period by the weighted average shares outstanding during the period. All outstanding stock options, non-vested restricted stock, warrants and common stock underlying convertible preferred stock, representing 1,534,095 and 456,010 incremental shares, have been excluded from the respective 2017 and 2016 computation of diluted EPS as they are anti-dilutive.

Stockholders_ Deficiency

Stockholders’ Deficiency	12 Months Ended
	Jul. 31, 2017
Equity [Abstract]
Stockholders’ Deficiency	Note 11 - Stockholders’ Deficiency: Common Stock On January 18, 2017, the Company issued 53,211 shares of common stock for the acquisition of 51% of HDS and is obligated to issue 230,000 shares of common stock upon the conclusion of the Company’s reverse stock split. As at year end the shares have yet to be issued. During January 2017, the Company issued 8,000 shares of common stock for the conversion of 120 shares of Series F convertible preferred stock, plus 4,235 shares for the related make-whole payments issued to convert the accumulated dividend payable. During January 2017, the Company issued 10,000 shares of common stock for the conversion of 150 shares of Series G convertible preferred stock, plus 4,688 shares for the related make-whole payments issued to convert the accumulated dividend payable. During February 2017, the Company issued 23,333 shares of common stock for the conversion of 350 shares of Series G convertible preferred stock, plus 10,606 shares for the related make-whole payments issued to convert the accumulated dividend payable. On February 9, 2017, the Company offered all current warrant holders an option to exercise immediately all outstanding common stock purchase warrants on a cashless basis at a reduced exercise price of $7.40 per share from $15.00 per share. The Company agreed to issue a total of 103,809 shares of common stock in connection with the exercise of 314,649 warrants in connection with the following outstanding warrants: Warrants Exercised Shares Agreed to be Issued Series C 9% Convertible Preferred Stock 10,000 3,299 Series D 9% Convertible Preferred Stock 16,649 5,492 Series E 9% Convertible Preferred Stock 119,667 39,481 Series F 9% Convertible Preferred Stock 138,333 45,639 Series G 9% Convertible Preferred Stock 30,000 9,898 314,649 103,809 As of the date of this filing, 31,195 shares have been issued and 72,614 shares remain to be issued resulting in additional common stock payable $1,071,851 as of July 31, 2017. Warrants As of July 31, 2016, the Company had 383,877 warrants with a current exercise price of $15 which have price protection provisions that allow for the reduction in the current exercise price upon the occurrence of certain events, including the Company’s issuance of common stock or securities convertible into or exercisable for common stock, such as options and warrants, at a price per share less than the exercise price then in effect. For instance, if the Company issues shares of its common stock or options exercisable for or securities convertible into common stock at an effective price per share of common stock less than the exercise price then in effect, the exercise price will be reduced to the effective price of the new issuance. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment. There are a limited number of permitted types of stock and equity instrument issuances for each series of warrants which will not invoke the price protection provisions of these warrants. The conversion price for all previously outstanding warrants was adjusted from $30.00 to $15.00 in conjunction with the Series G Convertible Preferred Stock financing on June 24, 2015 and the total number of previously outstanding warrants increased from 239,788 to 479,577, in addition to the 33,333 warrants issued in the financing. During the year ended July 31, 2016, 129,033 warrants, which had an exercise price of $15 per warrant, expired. There were no warrants exercised for the fiscal year ended July 31, 2016. The outstanding warrants at July 31, 2016 have a weighted average exercise price of $15 per share and have a weighted average remaining life of 2.1 years. As of July 31, 2016, there were a total of 383,877 warrants with an estimated fair value of $2,048,846, which were identified on the consolidated balance sheets under the caption “Derivative Warrant Liability”. During the year ended July 31, 2017, 65,896 warrants expired. There were 3,333 warrants exercised at an exercise price of $15.00 per share with proceeds of $50,000 for the year ended July 31, 2017 and 314,649 warrants were exercised on a cashless basis at a reduced exercise price of $7.40 issuing 103,809 shares of common stock. As of July 31, 2017, there are no warrants issued or outstanding. The Company accounts for the warrants with price protection provisions in accordance with FASB ASC Topic 815 as described in Note 12 - Derivative Liabilities Series A, B, C, D, E, F, and G 9% Convertible Preferred Stock All of the Company’s Series A, B, C, D and E 9% Convertible Preferred Stocks were converted prior to the beginning of the Company’s 2017 fiscal year. Series F and G 9% Convertible Preferred Stock The Company has authorized 4,150 shares of Series F 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated March 27, 2014, the Company sold an aggregate of 2,075 shares of Series F convertible preferred stock, as well as accompanying warrants to purchase 69,167 shares of common stock. An aggregate of 69,167 shares of the Company’s common stock were issuable upon conversion of the Series F convertible preferred stock which was issued at the closing on March 27, 2014. The Company has authorized 1,000 shares of Series G 9% Convertible Preferred Stock with a stated value of one thousand ($1,000) per share. Pursuant to a securities purchase agreement dated June 24, 2015, the Company sold an aggregate of 500 shares of Series G convertible preferred stock, as well as accompanying warrants to purchase 33,333 shares of common stock. An aggregate of 33,333 shares of the Company’s common stock are issuable upon conversion of the Series G convertible preferred stock which was issued at the closing on June 24, 2015. Subject to certain ownership limitations, the convertible preferred stock is convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $15.00 per share (Note: The conversion price for the Series F Convertible Preferred Stock was adjusted from $30.00 to $15.00 in conjunction with the Series G Convertible Preferred Stock financing on June 24, 2015 and in February 2017, the Company adjusted exercise further to $7.40 and all remaining outstanding warrants were exercised). Prior to conversion, the warrants, were entitled to accrue a 9% dividend until the third-year anniversary of the issuances. On each one-year anniversary thereafter, such dividend rate increased by an additional 3%. The dividend is payable quarterly on September 30, December 31, March 31 and June 30, beginning on June 30, 2014 and June 30, 2015, respectively, and on each conversion date in cash, or at the Company’s option, in shares of common stock. In the event that the Series F and G convertible preferred stock was converted prior to March 27, 2017 and June 24, 2018, respectively, the Company will pay the holder of the converted preferred stock an amount equal to $270 per $1,000 of stated value of the convertible preferred stock, less the amount of all prior quarterly dividends paid on such converted preferred stock before the relevant conversion date. Such “make-whole payment” may be made in cash or, at the Company’s option, in shares of its common stock. In addition, beginning on the third anniversary date of the issuances, the Company will pay dividends on shares of preferred stock equal to (on an as-if-converted-to-common-stock basis) and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, and if such dividends are paid. The Company will incur a late fee of 18% per annum on unpaid dividends. The conversion price of the convertible preferred stock was subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The conversion price was also to be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then conversion price, except in the event of certain exempt issuances. In addition, the holders of convertible preferred stock were entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had converted all of their shares of convertible preferred stock. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of convertible preferred stock were entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. The conversion price for the Series F Convertible Preferred Stock was adjusted from $30.00 to $15.00 in conjunction with the Series G Convertible Preferred Stock on June 24, 2015 and the number of common shares underlying the 838 Series F Convertible Preferred Stock outstanding at that date increased from 27,942 to 55,883 and the exercise price further adjusted from $15.00 to $7.40 during February 2017. In conjunction with the issuance of the Series F convertible preferred stock in March 2014 and the issuance of the Series G convertible preferred stock in June 2015, the Company also issued 69,167 and 33,333 warrants, respectively to the investors. Subject to certain ownership limitations, the warrants are exercisable at any time after their respective dates of issuance and on or before the fifth-year anniversary thereafter at an exercise price of $15.00 per share of common stock (Note: The conversion price for the warrants issued in the Series F Convertible Preferred Stock financing was adjusted from $30.00 to $15.00 in conjunction with the Series G Convertible Preferred Stock financing on June 24, 2015 and the number of warrants increased from 69,167 to 138,333; and in February 2017, the Company adjusted exercise further to $7.40 and all remaining outstanding warrants were exercised). Prior to conversion, the exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, was subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price and number of shares of common stock issuable upon exercise could have been also be adjusted if the Company sells or grants any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, the warrant holders had been entitled to receive any securities or rights to acquire securities or property granted or issued by the Company pro rata to the holders of its common stock to the same extent as if such holders had exercised all of their warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders could have been entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of the Company’s common stock pursuant to the fundamental transaction. Until such time that these warrants were exercised, these warrants had been classified as derivative liabilities and are described further in Note 12 - Derivative Liabilities . In addition, until the first anniversary date of the March 2014 securities purchase agreement and the first anniversary of the August 19, 2015 shareholder approval of the increase in authorized stock, respectively, each investor had the right, in its sole determination, to purchase, severally and not jointly with the other investors, in one or more purchases, in the ratio of such investor's original subscription amount to the original aggregate subscription amount of all investors, additional units consisting of convertible preferred stock and warrants at a purchase price of $1,000 per unit with an aggregate subscription amount thereof of up to $2,075,000 and $500,000, respectively, which units would have had terms identical to the units of convertible preferred stock and warrants issued in connection with the March 2014 and June 2015 closings. These additional investment rights of the investors had been classified as derivative liabilities and are described further in Note 12 - Derivative Liabilities . As of July 31, 2017, 2,075 of the Series F convertible preferred stock had been converted to common stock. There were 97,108 shares of common stock issued upon the conversion of the Series F convertible preferred stock and 40,769 shares of common stock issued as “make-whole payments” on such conversions. As of July 31, 2017, 500 of the Series G convertible preferred stock had been converted to common stock. There were 33,333 shares of common stock issued upon the conversion of the Series G convertible preferred stock and 15,294 shares of common stock issued as “make-whole payments” on such conversions. As of July 31, 2017, there were no shares of Series F and Series G convertible preferred stock outstanding. Accounting for proceeds from the Series F convertible preferred stock financing The initial cash proceeds, net of issuance costs of $55,000, from the Series F convertible preferred stock financing in March 2014 were $2,020,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing, second to the additional investment rights associated with the financing and then to the make whole payments and subsequent issuance costs. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statement of comprehensive (loss) / income for the fiscal year ended July 31, 2014 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 12 - Derivative Liabilities Accounting allocation of initial proceeds Net proceeds $ 2,020,000 Derivative warrant liability fair value (2,016,065 ) Derivative additional investment rights fair value (863,735 ) Other issuance costs (finders’ fee) (166,000 ) Make whole payments liability (560,250 ) Deemed dividend $ (1,586,050 ) The initial “make-whole payments” of $560,250 on the Series F convertible preferred stock were accrued as of the date of the financing. The remaining balance as of July 31, 2017 and July 31, 2016, after all conversions, are $-0- and $32,400, respectively, and is included in Accounts Payable and Accrued Expenses. Accounting for proceeds from the Series G convertible preferred stock financing The initial cash proceeds, net of issuance costs of $25,000, from the Series G convertible preferred stock financing in June 2015 were $475,000. The proceeds from the financing were allocated first to the warrants that were issued in the financing, second to the additional investment rights associated with the financing and then to the make whole payments and subsequent issuance costs. As the assigned fair values were greater than the net cash proceeds from the transaction, the excess was treated as a “deemed dividend” for accounting purposes and was reported on the Company’s consolidated statement of operations and comprehensive loss for the fiscal year ended July 31, 2015 under the caption “Preferred Stock Dividend”. The calculation methodologies for the fair values of the derivative warrant liability and the derivative additional investment rights liability are described in Note 12 - Derivative Liabilities Accounting allocation of initial proceeds Net proceeds $ 475,000 Derivative warrant liability fair value (354,535 ) Derivative additional investment rights fair value (285,048 ) Other issuance costs (finders’ fee) (40,000 ) Make whole payments liability (135,000 ) Deemed dividend $ (339,583 ) The initial “make-whole payments” of $135,000 on the Series G convertible preferred stock were accrued as of the date of the financing. The remaining balance as of July 31, 2017 and 2016, after all conversions, are $-0- and $135,000, respectively, and is in Accounts Payable and Accrued Expenses. Series H and Series I Convertible Preferred Stock The Company has authorized 109,000 shares of designated non-voting Series H Convertible Preferred Stock with a stated value of one thousand ($1,000) per share and authorized 6,000 shares of designated non-voting Series I Convertible Preferred Stock with a stated value of one thousand ($1,000) per share pursuant to the Purchase Agreement dated March 27, 2017. The Series H Preferred Stock was scheduled to be sold in four tranches to the Purchaser. Under the Securities Purchase Agreement, in the event the Purchaser failed to purchase 100% of the shares of Preferred Stock at any given Closing, the Company can decline to sell any further securities to the Purchaser (the Purchase Agreement”). The Series H and Series I Convertible Preferred Stock are convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $2.50 per share. An aggregate of 46,000,000 shares of the Company’s common stock would be issuable upon conversion of both the Series H and Series I Preferred Stock if all shares of such preferred stock contemplated by the securities purchase agreement are issued. Neither Series H nor Series I Convertible Preferred Stock have special dividend rights. If the Company pays dividends on its common stock, the holders of the preferred stock will receive dividends in the amount they would have received had they converted the preferred stock to common stock. The Series I Preferred Stock have a special one-time voting rights that provide at the first meeting of the Company’s stockholders following the initial issuance of the Preferred Stock, and all adjournments of such meeting, the Preferred Stock shall be entitled to vote on (i) the election of individuals to serve as members of the Board of Directors, and (ii) any proposal to increase the authorized number of shares of Common Stock. The Preferred Stock, as a class, shall be entitled to cast a number of votes on such proposal equal to fifty percent (50%) of the total number of votes entitled to be cast at such meeting (determined as of the record date for such meeting) by all other outstanding shares of the Company’s capital stock. Each share of Preferred Stock shall be entitled to cast a number of votes equal to the aggregate number determined pursuant to the last sentence divided by one thousand (1,000). At closing of the first tranche on March 28, 2017, the Company issued 3,000 shares of Series H Preferred Stock for a purchase price of $3,000,000. The proceeds of this sale were paid directly on the Company’s behalf to Emmaus as an additional deposit under the Company’s Emmaus LOI. An aggregate of 1,200,000 shares of the Company’s common stock are issuable upon conversion of the Series H Preferred Stock sold as of July 31, 2017. On April 17, 2017, the Purchaser failed to close the sale of Series I Preferred Stock despite the Company being ready, willing and able to proceed and the Company terminated the Purchaser’s rights on April 23, 2017. Under the Securities Purchase Agreement, in the event the Purchaser fails to purchase 100% of the shares of Preferred Stock, the Company can decline to sell any further securities to the Purchase. On April 23, 2017 the Company notified the Purchaser in writing that its rights to purchase additional shares were forfeit. Conversion of Debt to Officers into Series I Preferred Stock On April 27, 2017, the Company converted the “Moscato – Salvo Advances” (Note 6) after applying a 20% original issue discount, the same as the original issue discount negotiated at arm’s length with Alpha on March 6, 2017. Moscato converted $390,984 (including $65,164 original issue discount) into 391 shares of Series I Convertible Preferred Stock. Salvo converted $399,363 (including $66,560 original issue discount) into 399 shares of Series I Convertible Preferred Stock. The total original issue discount was $131,724 and was recorded as amortization of debt discount.

Derivative Liabilities

Derivative Liabilities	12 Months Ended
	Jul. 31, 2017
Notes to Financial Statements
Derivative Liabilities	Note 12 - Derivative Liabilities: Derivative warrant liability As of July 31, 2016, the Company had warrants outstanding with price protection provisions that allow for the reduction in the exercise price of the warrants in the event the Company subsequently issues stock or securities convertible into stock at a price lower than the exercise price of the warrants. Simultaneously with any reduction to the exercise price, the number of shares of common stock that may be purchased upon exercise of each of these warrants shall be increased or decreased proportionately, so that after such adjustment the aggregate exercise price payable for the adjusted number of warrants shall be the same as the aggregate exercise price in effect immediately prior to such adjustment. Accounting for Derivative Warrant Liability The Company’s derivative instruments have been measured at fair value at July 31, 2017 and July 31, 2016 using the binomial lattice model. The Company recognizes all of its warrants with price protection in its consolidated balance sheets as a liability. The liability is revalued at each reporting period and changes in fair value are recognized currently in the consolidated statements of operations and comprehensive loss. The initial recognition and subsequent changes in fair value of the derivative warrant liability have no effect on the Company’s consolidated cash flows. There are no derivative warrants outstanding at July 31, 2017. The revaluation of the warrants at the end of the respective reporting periods resulted in the recognition of a gain of $516,509 within the Company’s consolidated statements of operations for the year ended July 31, 2017 and a gain of $314,569 within the Company’s consolidated statements of operations and comprehensive loss for the year ended July 31, 2016, which are included in the consolidated statement of operations and comprehensive loss under the caption “Change in fair value of derivative liabilities”. The fair values of the warrants at July 31, 2017 and July 31, 2016 were $0 and $2,048,846, respectively, which are reported on the consolidated balance sheets under the caption “Derivative Warrant Liability”. The following summarizes the changes in the value of the derivative warrant liability from July 31, 2016 until July 31, 2017: Value No. of Warrants Balance at July 31, 2015 - Derivative warrant liability $ 2,363,415 512,911 Forfeited or expired (455,573 ) (129,033 ) Increase in fair value of derivative warrant liability 141.004 n/a Balance at July 31, 2016 - Derivative warrant liability 2,048,846 383,878 Forfeited or expired (240,906 ) (65,896 ) Warrants exercised (1,532,336 ) (317,982 ) Decrease in fair value of derivative warrant liability (275,604 ) n/a Balance at July 31, 2017 - Derivative warrant liability $ — — Fair Value Assumptions Used in Accounting for Derivative Warrant Liability The Company has determined its derivative warrant liability to be a Level 2 fair value measurement and has used the binominal lattice pricing model to calculate the fair value as of July 31, 2016. The binomial lattice model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Because the warrants contain the price protection feature, the probability that the exercise price of the warrants would decrease as the stock price decreased was incorporated into the valuation calculations. The key inputs used in the July 31, 2016 fair value calculations were as follows: July 31, 2016 Current exercise price $ 15.00 Time to expiration 2.1 years Risk-free interest rate 0.76 % Estimated volatility 101 % Dividend — Stock price at year end $ 8.00 Fair Value Assumptions Used in Accounting for Derivative Additional Investment Rights Liability The Company has determined the derivative additional investment rights liability derived from the issuance of Preferred stock financing Series G shares (Note 11) to be a Level 2 fair value measurement and has used the binominal lattice pricing model to measure the fair value. The series F additional investment rights expired in March 2015. The series G additional investment rights expired in August 2016. As all additional investment rights have expired, their value at July 31, 2017 was $nil (July 31, 2016 - $193,408). The key inputs used in the fair value calculation at July 31, 2016 were as follows: July 31, 2016 Underlying number of units of convertible preferred stock 500 Underlying number of units of warrants 33,333 Current exercise price of warrants $ 15.00 Current conversion price of preferred stock $ 15.00 Time to expiration 0.05 years Risk-free interest rate 0.38 % Estimated volatility 13 % Dividend -0- Stock price at year end $ 8.00 The revaluation of the additional investment rights in the year ended July 31, 2017 and 2016, resulted in the recognition of a gain of $193,408 and a loss of $50,746, respectively. The respective gains are recorded within the Company’s consolidated statements of operations and comprehensive loss under the caption “Change in fair value of derivative liabilities”.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation:	Note 13 - Stock-Based Compensation Stock Option Plans As of July 31, 2017, the Company had two stockholder-approved stock incentive plans under which shares and options exercisable for shares of common stock have been or may be granted to employees, directors, consultants and advisors. A total of 12,000 shares of common stock are reserved for issuance under the 2001 Stock Option Plan (the 2001 Plan) and 135,000 shares of common stock are reserved for issuance under the 2006 Stock Plan as amended (the 2006 Plan). At July 31, 2017, there were 4,139 and 64,485 shares of common stock reserved for future awards under the 2001 Plan and 2006 Plan, respectively. The Company issues new shares of common stock from the shares reserved under the respective Plans upon conversion or exercise of options and issuance of restricted shares. The 2001 and 2006 Plans (the Plans) are administered by the Board of Directors (the Board). The Board is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom options are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Board is also authorized to prescribe, amend and rescind terms relating to options granted under the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Board. The Plans provide that options may or may not be Incentive Stock Options (ISOs) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options which are not ISOs, i.e. “Non-Qualified Options.” The options granted by the Board in connection with its adoption of the Plans were Non-Qualified Options. In addition, the 2006 Plan also provides for restricted stock grants. Share-based employee compensation related to stock options for the years ended July 31, 2017 and 2016 amounted to $-0- and $30,297 respectively, and were charged to the consolidated statements of operations and comprehensive loss. In addition, during 2016 the Company issued 15,393 stock options in satisfaction of deferred compensation amounts totaling $123,147 owing to executives at that time. Share-based employee compensation related to common stock grants for the years ended July 31, 2017 and 2016 amounted to $-0- for both fiscal years. The fair value of each option granted is estimated on the grant date using the Black-Scholes option pricing model or the value of the services provided, whichever is more readily determinable. The Black-Scholes option pricing model takes into account, as of the grant date, the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the option. The Black-Scholes option pricing model was not used to estimate the fair value of any option grants in the fiscal years ended July 31, 2017 and 2016. Instead, the grants were valued at the amount of deferred compensation owed to each such individual. The following is a summary of the common stock options granted, forfeited or expired and exercised under the Plan: Options Weighted Average Exercise Price per Share Outstanding - July 31, 2015 30,233 $ 50.00 Granted 18,345 $ 1.00 Forfeited or expired (3,000 ) $ 280.00 Exercised (25,939 ) $ 1.00 Outstanding - July 31, 2016 19,639 $ 30.00 Forfeited or expired (1,544 ) $ 1.00 Outstanding - July 31, 2017 18,095 $ 31.02 Exercisable - July 31, 2017 18,095 $ 31.02 The 18,095 outstanding options at July 31, 2017 had a weighted average remaining contractual term of 1.11 years. There were no non-vested common stock options granted, vested or forfeited under the Plan for the fiscal year ended July 31, 2017. As of July 31, 2017, the Company did not have any unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. During the year ended July 31, 2016, the Company granted 18,345 options to executives, employees and directors in full and final payment of obligations to pay such individuals deferred salary or director fees. The options were issued in lieu of cash payment of deferred compensation amounts due to such individuals. The stock options had an exercise price equal to $1 per share and were made pursuant to the terms of the Company's 2006 Stock Plan. The options were fully vested at the dates of the grants and expire on the fifth anniversary of the respective dates of grant. The grants were valued at the amount of deferred compensation owed to each such individual. The Company did not grant any options during the twelve months ended July 31, 2017. The following table summarizes information on stock options outstanding at July 31, 2017: Options Outstanding and Options Exercisable Range of Exercise Price Number Outstanding at July 31, 2017 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 1.00 17,245 $ 1.00 1.04 69,843 $ 640.00 850 $ 640.00 2.61 - 18,095 $ 31.02 1.11 $ 69,843 For the Years Ended July 31, 2017 2016 Aggregate Intrinsic Value of Options Exercised $ -0- $ 363,151 Cash Received for Exercise of Stock Options $ -0- $ 2,952 The intrinsic value is calculated as the difference between the market value as of July 31, 2017 and 2016 and the exercise price of the shares on the respective dates. The market values as of July 31, 2017 and 2016 were $5.05 and $79.00, respectively, based on the high and low bid information for July 31, 2017 and 2016.

Acquisition of Hema Diagnostics

Acquisition of Hema Diagnostics Systems, LLC	12 Months Ended
	Jul. 31, 2017
Business Combinations [Abstract]
Acquisition of Hema Diagnostics Systems, LLC	Note 14 - Acquisition of Hema Diagnostics Systems, LLC On January 18, 2017, the Company acquired a 51% interest in Hema Diagnostic Systems, LLC (“HDS”), pursuant to the Acquisition Agreement. At closing, the Company acquired 4,950 of HDS’s 10,000 previously outstanding limited liability company units in exchange for 53,191 shares of Generex common stock valued at $253,721, plus 20 shares of Generex common stock issued to HDS in exchange for 300 new limited liability company units. The Acquisition Agreement also provides the Company with a call option to acquire the remaining 49% of HDS and a retirement of HDS shareholder loans in the amount of $13,431,706 (including interest) (the “Call Option”) for the aggregate purchase price of $1. Following the closing and the completion of Company’s reverse stock split, the Company is required to issue a further 230,000 shares of common stock and issue a warrant to a former shareholder of HDS to acquire 15,000,000 additional shares of Generex common stock for $2.50 per share. The issue of this warrant is contingent upon the Company obtaining approval from its shareholders for an increase in its authorized share capital. The total consideration was valued at $1,350,916 on the date of the acquisition. Fair Value of the HDS Assets The intangibles assets acquired include In–Process Research & Development (“IPR&D”). The Fair Value of the IPR&D intangible asset using an Asset Cost Accumulation methodology as of January 18, 2017 (the “Valuation Date”) was determined to be $2,911,377. The net purchase price of HDS was determined to be as follows: Stock Price at Closing Shares Fair Value Purchase price: Common Stock at closing $ 4.77 53,191 $ 253,721 Common Stock after closing $ 4.77 20 95 Common Stock post reverse stock split $ 4.77 230,000 1,097,100 Total purchase price $ 1,350,916 As of January 18, 2017, the issue of the warrant to acquire 15,000,000 additional common shares of Generex was contingent upon shareholder approval of an increase in the Company’s authorized capital stock. No warrant has been issued by the Company until such time that an increase in authorized capital has been approved. At the time of closing, Management was not of the opinion that it is more likely than not that the warrant will be issued and the Call Option will be exercised, accordingly no values have been attributed to the warrant and Call Option at closing. During the current year, management made a redetermination and estimated that it was more likely than not that the shareholder approval to increase authorized share capital would be obtained and the Call Option will be exercised. Accordingly, management recorded the fair value of the warrant of $66,060,026 as a liability and the Call Option of $4,237,829 as an asset as of July 31, 2017. The change in the fair value of the contingent purchase consideration of $61,822,197 is recorded in the consolidated statements of operations and comprehensive loss. Fair Value Assumptions Used in Accounting for Warrants The Company used the Black-Scholes option-pricing model to calculate the fair value of the warrants as of July 31, 2017. The Black-Scholes option-pricing model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. The key inputs used in the fair value calculations were as follows: July 31, 2017 Exercise price 2.50 Time to expiration 4.47 years Risk-free interest rate 1.84 % Estimated volatility 122.7 % Dividend — Stock price at valuation date $ 5.05 Fair Value Assumptions Used in Accounting for Call Option The Company used the Monte Carlo model to calculate the fair value of the call option as of July 31, 2017. The valuations are based on assumptions as of the valuation date with regard to the value of the asset acquired net of impairment, the risk-free interest rate, the estimated volatility of the stock price in the future, the time to expiration and the stock price at the date of valuation. The following assumptions were used in estimating the value of the Call Option: July 31, 2017 Risk-free interest rate 1.34 % Estimated volatility 143.9 % Remaining Term 2.47 Stock price at valuation date $ 5.05 The preliminary purchase price allocation of HDS was determined to be as follows: Cash and cash equivalents 12,363 Accounts receivable, net 980 Inventory, net 21,141 Other current assets 91,474 Property and equipment, net 4,249 Other assets, net 39,675 Accounts payable and accrued expenses (489,390 ) Loan to related parties (13,323,391 ) Net assets of HDS (13,642,899 ) Non-controlling interest (1,297,939 ) In-Process Research & Development 2,911,377 Goodwill 13,380,377 Total Purchase Price 51% Ownership $ 1,350,916 Goodwill and Intangible Assets The change in the carrying amount of goodwill and other intangible assets for the year ended July 31, 2017, is as follows: Total Goodwill Other Intangibles, net Balance as of July 31, 2016 $ — $ — $ — Acquisition of HDS 16,291,754 13,380,377 2,911,377 Current year amortization — — — Impairment of goodwill (13,380,377 ) (13,380,377 ) — Balance as of July 31, 2017 $ 2,911,377 $ — $ 2,911,377 Intangible assets are generally amortized on a straight-line basis over the useful lives of the assets. The Company is currently not amortizing the in-process research and development until it becomes commercially viable and placed in service. At the time when the intangible assets are placed in service the Company will determine a useful life. Goodwill represents the excess of the purchase price over the fair market value of net assets acquired. Goodwill for HDS was $13.4 million as of the date of the acquisition. The Company conducted an impairment assessment of goodwill and determined that the goodwill was fully impaired.

Segment Information

Segment Information	12 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Segment Reporting	Note 15 - Segment Information The Company follows FASB ASC Topic 815 which establishes standards for the way that public business enterprises report information about operating segments in annual financial statements and requires that those enterprises report selected information about operating segments in financial reports. This Topic also establishes standards for related disclosures about products and services, geographic areas, and major customers. This Topic uses a management approach for determining segments. The management approach designates the internal organization that is used by management for making operating decisions and assessing performance as the source of the Company’s reportable segments. The Company’s management reporting structure provides for only one segment: the research, development and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. The countries in which the Company had identifiable assets are presented in the following table. Identifiable assets are those that can be directly associated with a geographic area. 2017 2016 Identifiable Assets Canada $ 2,881,326 $ 25,930 United States 7,213,219 344 Total $ 10,094,545 $ 26,274

Subsequent Events

Subsequent Events	12 Months Ended
	Jul. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 16 - Subsequent Events: The Company has evaluated subsequent events occurring after the balance sheet date through the date the interim consolidated financial statements were issued and identified the following for disclosure: Since July 31, 2017, the former majority shareholder of HDS has made further advances and/or loans to HDS totaling $94,000 as of the date of this filing. On August 24, 2017, the Company and Core Tech Solutions, Inc. (“Core Tech”) entered into a letter of intent (“LOI”) contemplating Company’s acquisition of a controlling interest of the outstanding capital stock of Core Tech for a total consideration of $15,000,000 in accordance with the terms and conditions therein.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and all of its wholly-owned and majority-owned subsidiaries. All significant intercompany transactions and balances have been eliminated. The subsidiaries included in the Company’s consolidated financial statements are: Generex Pharmaceuticals, Inc.; Generex (Bermuda), Inc.; Antigen Express, Inc.; 1097346 Ontario, Inc.; Hema Diagnostics Systems, LLC; Hema Diagnostics Systems Panama S.A.; Rapid Medical Diagnostics Corporation. Provided, however, that in the event that the Purchasers fail to purchase 100% of the shares of Preferred Stock at any given Closing (other than the Closing Series H Tranche One) notwithstanding that the Company is ready, willing, and able to effect such Closing in accordance with the terms and conditions of this Agreement (a “Failure to Purchase Event”), then: (i) the Purchasers’ entitlement to purchase any Preferred Stock in respect of that Closing and any and all subsequent Closings under this Agreement is forfeit in total, (ii) the Company shall have no obligation to issue any further Securities to the Purchasers under this Agreement, and (iii) the Company shall have no recourse against the Purchasers, at law or in equity, in respect of such Failure to Purchase Event. For greater certainty, any securities that would otherwise have been issuable by the Company to the Purchasers but for the Failure to Purchase Event shall not be Securities (as that term is defined in this Agreement) and the Company shall have no registration obligation in respect thereof under the Registration Rights Agreement.
Business Combinations	Business Combinations Business combinations are accounted for using the acquisition method of accounting. Acquisition cost is measured as the aggregate of the fair value at the date of acquisition of the assets given, equity instruments issued or liabilities incurred or assumed. Acquisition related costs are expensed as incurred (except for those costs arising on the issue of equity instruments which are recognized directly in equity). Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured at fair value on the acquisition date. Goodwill is measured as the excess of the acquisition cost and the amount of any non-controlling interest, over the fair value of the identifiable net assets acquired.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers
Inventory	Inventory Inventory is stated at the lower of cost or net realizable value. Cost is determined using the Weighted Average method. The Company periodically evaluates its inventory for any obsolete or slow moving items based on production lot number and advances in production design or technology. Any inventory determined to be obsolete or slow moving inventory is written down to its net realizable value.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on the straight-line method over the estimated useful lives of the assets, which range from three to seven years. Gains and losses on depreciable assets retired or sold are recognized in the consolidated statement of operations and comprehensive loss in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.
Patents	Patents Capitalized patent costs represent legal costs incurred to establish patents and a portion of the acquisition price paid attributed to patents upon the acquisition of Antigen in August 2003 and the acquisition of HDS in January 2017. When patents reach a mature stage, any associated legal costs are comprised mostly of maintenance fees and costs of national applications and are expensed as incurred. Capitalized patent costs are amortized on a straight line basis over the remaining life of the patent. As patents are abandoned, the net book value of the patent is written off.
In-process Research & Development	In-process Research & Development: The costs of in-process research and development (“IPR&D”), related to the Company’s business combination with HDS, were recorded at fair value on the acquisition date. IPR&D intangible assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired.
Impairment or Disposal of Long-Lived Assets and Intangibles	Impairment or Disposal of Long-Lived Assets and Intangibles The Company assesses the impairment of long-lived assets under FASB ASC Topic 360 whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable and exceeds its fair value. The carrying amount of the long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposal of the asset.
Derivative Warrant Liability	Derivative Warrant Liability The Company’s derivative warrant instruments are measured at fair value using the binomial valuation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock and its expected volatility, expected dividends on the stock and the risk-free interest rate for the term of the warrant. The liability is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss under the caption “Change in fair value of derivative liabilities.”
Research and Development Costs	Research and Development Costs Expenditures for research and development are expensed as incurred and include, among other costs, those related to the production of experimental drugs, including payroll costs, and amounts incurred for conducting clinical trials. Amounts expected to be received from governments under research and development tax credit arrangements are offset against current research and development expense.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method prescribed by FASB ASC Topic 740. These standards require a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more likely than not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. At The Company adopted the FASB guidance concerning accounting for uncertainty in income taxes, which clarifies the accounting and disclosure for uncertainty in tax positions, as of August 1, 2007. The guidance requires that the Company determine whether it is more likely than not that a tax position will not be sustained upon examination by the appropriate taxing authority. If a tax position does not meet the more likely than not recognition criterion, the guidance requires that the tax position be measured at the largest amount of benefit greater than 50 percent not likely of being sustained upon ultimate settlement. Based on the Company’s evaluation, management has concluded that there are no significant uncertain tax positions requiring recognition in the consolidated financial statements.
Stock-Based Compensation	Stock-Based Compensation The Company follows FASB ASC Topic 718 which requires that new, modified and unvested share-based payment transactions with employees, such as grants of stock options and restricted stock, be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over their vesting periods. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the quoted market price or the value of the services provided, whichever is more readily determinable. The Company also follows the guidance in FASB ASC Topic 505 for equity based payments to non-employees for equity instruments issued to consultants and other non-employees.
Net Loss per Common Share	Net Loss per Common Share Basic earnings per share is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share gives effect to all dilutive potential common shares outstanding during the period. The computation of diluted earnings per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings.
Comprehensive Income/(Loss)	Comprehensive Income/(Loss) Other comprehensive income/(loss), which includes only foreign currency translation adjustments, is shown in the consolidated statements of operations and comprehensive loss and in the consolidated statements of changes in stockholders’ deficiency.
Foreign Currency Translation	Foreign Currency Translation The functional and reporting currency of the Company and most of its subsidiaries is the United States Dollar. One subsidiary, Generex Pharmaceuticals, Inc., has a functional currency of the Canadian Dollar. Foreign denominated assets and liabilities of the Company are translated into U.S. dollars at the prevailing exchange rates in effect at the end of the reporting period. Income statement accounts are translated at an average of exchange rates which were in effect during the period. Translation adjustments that arise from translating the foreign subsidiary’s financial statements from its functional currency to the Company’s functional currency are recorded in the other comprehensive loss component of stockholders’ equity. Gains and losses resulting from foreign currency transactions are included in the statement of operations and comprehensive loss.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined under FASB ASC Topic 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for an asset or liability in an orderly transaction between participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The levels are as follows: • Level 1 - Quoted prices in active markets for identical assets or liabilities • Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data for substantially the full term of the assets or liabilities • Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities The Company’s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses, call option, warrants to be issued, derivative warrant liability, derivative additional investment right liability, loans payable and loans from related parties. All of these items, except of the call option, derivative warrant liability, derivative additional investment right liability and warrants to be issued, were determined to be Level 1 fair value measurements. The carrying amounts of cash and cash equivalents, other current assets, accounts payable and accrued expenses and the loans from related parties approximate their respective fair values because of the short maturities of these instruments. The call option, derivative warrant liability, derivative additional investment right liability and warrants to be issued, were determined to be Level 2 fair value measurements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company evaluates its estimates, including those related to long lived assets (including patents) impairment valuations, derivatives and contingencies and litigation, on an ongoing basis. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Critical accounting estimates are reviewed and discussed with the Board of Directors. The Company considers an accounting estimate to be critical if it requires assumptions to be made that were uncertain at the time the estimate was made, if changes in the estimate or if different estimates that could have been selected would have a material impact on our results of operations or financial condition.
Effects of Recent Accounting Pronouncements	Effects of Recent Accounting Pronouncements: Recently Issued Accounting Pronouncements We have reviewed the FASB issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effective dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15 and does not expect any material impact on the Company’s consolidated financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Jul. 31, 2017
Property, Plant and Equipment [Abstract]
Property and Equipment	July 31, 2017 2016 Equipment $ 82,602 $ — Leasehold Improvements 40,445 — Furniture and Fixtures 1,402 10,900 Less: Accumulated depreciation 123,876 9,602 Property and Equipment, net $ 573 $ 1,298

Patents (Tables)

Patents (Tables)	12 Months Ended
	Jul. 31, 2017
Accounting Policies [Abstract]
Costs and accumulated amortization of patents	Beginning balance as of August 1, 2015 $ 1,430,016 Additions 17,742 Less: Amortization expense 281,894 Write-off due to abandonment (1,165,864 ) Patents, net as of July 31, 2016 — Net patents acquired during acquisition of HDS 27,221 Less: Amortization expense 1,370 Patents, net as of July 31, 2017 $ 25,851 Weighted average life 9 years

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2017
Income Tax Disclosure [Abstract]
Deferred income taxes	July 31, 2017 2016 Net operating loss carryforwards $ 88,428,273 $ 86,895,338 Other temporary differences 4,132,264 150,004 Intangible assets — — Total Deferred Tax Assets 92,560,537 87,045,342 Valuation Allowance (92,560,537 ) (86,678,987 ) Deferred Tax Liabilities Intangible assets (- ) (366,355 ) Other temporary differences — — Total Deferred Tax Liabilities — — Net Deferred Income Taxes $ — $ —
Reconciliation of effective tax rate	July 31, 2017 2016 Federal statutory rate (34.0 )% (34.0 )% Increase (decrease) in income taxes resulting from: Imputed interest income on intercompany receivables from foreign subsidiaries 0 4 Non-deductible or non-taxable items 27 (3 ) Other temporary differences (1 ) 26 Change in valuation allowance 8 7 Effective tax rate — % — %

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	12 Months Ended
	Jul. 31, 2017
Schedule of warrants exercised	Warrants Exercised Shares Agreed to be Issued Series C 9% Convertible Preferred Stock 10,000 3,299 Series D 9% Convertible Preferred Stock 16,649 5,492 Series E 9% Convertible Preferred Stock 119,667 39,481 Series F 9% Convertible Preferred Stock 138,333 45,639 Series G 9% Convertible Preferred Stock 30,000 9,898 314,649 103,809
Series F Convertible Preferred Stock
Allocation of initial proceeds	Accounting allocation of initial proceeds Net proceeds $ 2,020,000 Derivative warrant liability fair value (2,016,065 ) Derivative additional investment rights fair value (863,735 ) Other issuance costs (finders’ fee) (166,000 ) Make whole payments liability (560,250 ) Deemed dividend $ (1,586,050 )
Series G Convertible Preferred Stock
Allocation of initial proceeds	Accounting allocation of initial proceeds Net proceeds $ 475,000 Derivative warrant liability fair value (354,535 ) Derivative additional investment rights fair value (285,048 ) Other issuance costs (finders’ fee) (40,000 ) Make whole payments liability (135,000 ) Deemed dividend $ (339,583 )

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	12 Months Ended
	Jul. 31, 2017
Notes to Financial Statements
Derivative warrant liability	Value No. of Warrants Balance at July 31, 2015 - Derivative warrant liability $ 2,363,415 512,911 Forfeited or expired (455,573 ) (129,033 ) Increase in fair value of derivative warrant liability 141.004 n/a Balance at July 31, 2016 - Derivative warrant liability 2,048,846 383,878 Forfeited or expired (240,906 ) (65,896 ) Warrants exercised (1,532,336 ) (317,982 ) Decrease in fair value of derivative warrant liability (275,604 ) n/a Balance at July 31, 2017 - Derivative warrant liability $ — —
Fair value assumptions, derivative warrant liability	July 31, 2016 Current exercise price $ 15.00 Time to expiration 2.1 years Risk-free interest rate 0.76 % Estimated volatility 101 % Dividend — Stock price at year end $ 8.00
Fair value assumptions, derivative additional investment rights liability	July 31, 2016 Underlying number of units of convertible preferred stock 500 Underlying number of units of warrants 33,333 Current exercise price of warrants $ 15.00 Current conversion price of preferred stock $ 15.00 Time to expiration 0.05 years Risk-free interest rate 0.38 % Estimated volatility 13 % Dividend -0- Stock price at year end $ 8.00

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jul. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common stock options granted, forfeited or expired and exercised	Options Weighted Average Exercise Price per Share Outstanding - July 31, 2015 30,233 $ 50.00 Granted 18,345 $ 1.00 Forfeited or expired (3,000 ) $ 280.00 Exercised (25,939 ) $ 1.00 Outstanding - July 31, 2016 19,639 $ 30.00 Forfeited or expired (1,544 ) $ 1.00 Outstanding - July 31, 2017 18,095 $ 31.02 Exercisable - July 31, 2017 18,095 $ 31.02
Information on stock options outstanding	Options Outstanding and Options Exercisable Range of Exercise Price Number Outstanding at July 31, 2017 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $ 1.00 17,245 $ 1.00 1.04 69,843 $ 640.00 850 $ 640.00 2.61 - 18,095 $ 31.02 1.11 $ 69,843
Intrinsic value of stock options	For the Years Ended July 31, 2017 2016 Aggregate Intrinsic Value of Options Exercised $ -0- $ 363,151 Cash Received for Exercise of Stock Options $ -0- $ 2,952

Acquisition of Hema Diagnosti30

Acquisition of Hema Diagnostics Systems, LLC (Tables)	12 Months Ended
	Jul. 31, 2017
Business Combinations [Abstract]
Net purchase price of HDS	Stock Price at Closing Shares Fair Value Purchase price: Common Stock at closing $ 4.77 53,191 $ 253,721 Common Stock after closing $ 4.77 20 95 Common Stock post reverse stock split $ 4.77 230,000 1,097,100 Total purchase price $ 1,350,916
Preliminary purchase price allocation of HDS	Cash and cash equivalents 12,363 Accounts receivable, net 980 Inventory, net 21,141 Other current assets 91,474 Property and equipment, net 4,249 Other assets, net 39,675 Accounts payable and accrued expenses (489,390 ) Loan to related parties (13,323,391 ) Net assets of HDS (13,642,899 ) Non-controlling interest (1,297,939 ) In-Process Research & Development 2,911,377 Goodwill 13,380,377 Total Purchase Price 51% Ownership $ 1,350,916
Fair Value Assumptions Used in Accounting for Warrants	July 31, 2017 Exercise price 2.50 Time to expiration 4.47 years Risk-free interest rate 1.84 % Estimated volatility 122.7 % Dividend — Stock price at valuation date $ 5.05
Fair Value Assumptions Used in Accounting for Call Options	July 31, 2017 Risk-free interest rate 1.34 % Estimated volatility 143.9 % Remaining Term 2.47 Stock price at valuation date $ 5.05
Carrying amount of goodwill and other intangible assets	Total Goodwill Other Intangibles, net Balance as of July 31, 2016 $ — $ — $ — Acquisition of HDS 16,291,754 13,380,377 2,911,377 Current year amortization — — — Impairment of goodwill (13,380,377 ) (13,380,377 ) — Balance as of July 31, 2017 $ 2,911,377 $ — $ 2,911,377

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Jul. 31, 2017
Segment Reporting [Abstract]
Segment Information	2017 2016 Identifiable Assets Canada $ 2,881,326 $ 25,930 United States 7,213,219 344 Total $ 10,094,545 $ 26,274

Organization of Business and Go

Organization of Business and Going Concern (Details Narrative)	12 Months Ended
	Jul. 31, 2017USD ($)	Jan. 18, 2017
Reverse stock split ratio	0.001
Accumulated deficit	$ 446,000,000
Working capital deficiency	$ 21,000,000
Hema Diagnostic Systems, LLC
Majority interest		51.00%

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Accounting Policies [Abstract]
Write down of certain patents		$ 1,165,864

Property and Equipment - Long L

Property and Equipment - Long Lived Assets (Details) - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Less: Accumulated Depreciation	$ 123,876	$ 9,602
Property and Equipment, Net	573	1,298
Equipment [Member]
Property, Plant and Equipment, Gross	82,602
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	40,445
Furniture and Fixtures
Property, Plant and Equipment, Gross	$ 1,402	$ 10,900

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,675	$ 1,517

Patents - Costs and accumulated

Patents - Costs and accumulated amortization of patents (Details) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Accounting Policies [Abstract]
Patents		$ 1,430,016
Additions		17,742
Net patents acquired during acquisition of HDS	27,221
Less: Amortization expense	1,370	281,894
Write-off due to abandonment	1,165,864
Patents, Net	$ 25,851
Weighted Average Life	9 years

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Accounting Policies [Abstract]
Amortization expense, patents	$ 1,370	$ 281,894
Write-off of abandoned patents	$ 1,165,864

Income Taxes - Deferred income

Income Taxes - Deferred income taxes (Details) - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 88,428,273	$ 86,895,338
Other temporary differences	4,132,264	150,004
Intangible assets
Total Deferred Tax Assets	92,560,537	87,045,342
Valuation Allowance	(92,560,537)	(86,678,987)
Deferred Tax Liabilities
Intangible assets		(366,355)
Other temporary differences
Total Deferred Tax Liabilities
Net Deferred Income Taxes

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of effective tax rate (Details)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Income Tax Disclosure [Abstract]
Federal statutory rate	(34.00%)	(34.00%)
Increase (decrease) in income taxes resulting from:
Imputed interest income on intercompany receivables from foreign subsidiaries	0.00%	400.00%
Nondeductible or non-taxable items	2700.00%	(300.00%)
Other temporary differences	(100.00%)	2600.00%
Change in valuation allowance	800.00%	700.00%
Effective tax rate	0.00%	0.00%

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Pretax losses arising from domestic operations	$ (76,823,599)	$ (1,374,725)
Pretax losses arising from foreign operations	(869,116)	$ (504,101)
Generex Biotechnology Corporation
NOL carryforwards, expiring through 2036	200,000,000
Generex Pharmaceuticals, Inc
NOL carryforwards, expiring through 2036	34,700,000
Antigen Express, Inc
NOL carryforwards, expiring through 2036	$ 31,300,000

Loan from Related Parties (Deta

Loan from Related Parties (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2017	Jul. 31, 2016	Apr. 27, 2017	Jan. 16, 2017
Paid to Emmaus Life Sciences, Inc					$ 500,000
Retirement of debt				$ 658,622
Increase in loan payable		$ 1,171,021
Hema Diagnostic Systems, LLC
Outstanding balance	$ 13,738,140	13,738,140
Increase in loan payable	498,303
Salvo
Unsecured advance	82,803	82,803			250,000
Moscato
Unsecured advance	$ 75,820	$ 75,820			$ 250,000

Loan Payable (Details Narrative

Loan Payable (Details Narrative)	1 Months Ended
	May 31, 2016USD ($)
Notes to Financial Statements
Unsecured note	$ 50,000
Unsecured note interest per annum	9.00%

Convertible Note Payable (Detai

Convertible Note Payable (Details Narrative) - USD ($)	7 Months Ended	12 Months Ended
	Mar. 06, 2017	Jul. 31, 2017
Notes to Financial Statements
Convertbile Note Issued	$ 674,855
Interest rate if note defaults	15.00%
Consideration received	$ 562,379
Cash received	500,000
Cancellation of note	50,000
Cancellation of accrued interest	3,879
Cancellation of legal fees	$ 8,500
Conversion rate per share	$ 10
Debt discount	$ 120,976
Original issue discount	$ 112,476
Amortization of debt discount		$ 120,976
Effective interest rate		19.91%

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended	12 Months Ended
	Aug. 22, 2017	Jul. 31, 2017	Jan. 16, 2017	Nov. 16, 2012	Jul. 31, 2012	Jul. 31, 2011
Commitments and Contingencies	The letter from AEXG counsel claimed that Generex’s acceptance of $3,000,000 in financing form Pharma Trials, LLC, in March 2017, violated the provisions of the MOU prohibiting Generex from seeking other financing, with certain exceptions, for a period of 60 days after execution of the MOU. AEXG has demanded at least $210,000 in cash and 84,000 warrants for Generex stock convertible at $2.50 per share, for attorney’s fees and costs.  Generex management believes the Pharma Trials, LLC Financing was not subject to the prohibitions because the representative of Pharma Trials, LLC was a director of Generex, and for other reasons.
Damages for Unpaid Invoices
Value of damages sought					$ 429,000
Lawsuit filing date					31-Dec-11
Name of Plaintiff					Vendor
Settlement of litigation				$ 125,000
Interest per annum, failure to pay settlement					3.00%
Fixed cost per annum, failure to pay settlement					$ 25,000
Punitive Damages
Value of damages sought						$ 50,000
Breach of contract and detinue
Value of damages sought						550,000
Counterclaim proceeding						$ 200,000
Lawsuit filing date						1-Jun-11
Name of Plaintiff						Golden Bull Estates
Termination Of Employee
Value of damages sought						$ 7,000,000
Lawsuit filing date						20-May-11
Name of Plaintiff						Ms. Perri
Deposit
Payment to Emmaus		$ 4,000,000
Shares
Consideration to acquire controlling interest of capital stock			$ 215,000,000
Cash
Consideration to acquire controlling interest of capital stock			10,000,000
Emmaus
Consideration to acquire controlling interest of capital stock			$ 225,000,000

Net (Loss) _ Per Share (EPS) (D

Net (Loss) / Per Share (EPS) (Details Narrative) - shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Accounting Policies [Abstract]
Incremental shares	1,534,095	456,010

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Warrants Exercised (Details)	12 Months Ended
	Jul. 31, 2017shares
Warrants exercised	314,649
Shares Agreed to be Issued	103,809
Series C Convertible Preferred Stock
Warrants exercised	10,000
Shares Agreed to be Issued	3,299
Series D Convertible Preferred Stock
Warrants exercised	16,649
Shares Agreed to be Issued	5,492
Series E Convertible Preferred Stock
Warrants exercised	119,667
Shares Agreed to be Issued	39,481
Series F Convertible Preferred Stock
Warrants exercised	138,333
Shares Agreed to be Issued	45,639
Series G Convertible Preferred Stock
Warrants exercised	30,000
Shares Agreed to be Issued	9,898

Stockholders' Deficiency - Allo

Stockholders' Deficiency - Allocation of initial proceeds (Details)	12 Months Ended
	Jul. 31, 2017USD ($)
Series F Convertible Preferred Stock
Net proceeds	$ 2,020,000
Derivative warrant liability fair value	(2,016,065)
Derivative additional investment rights fair value	(863,735)
Other issuance costs (finders' fee)	(166,000)
Make whole payments liability	(560,250)
Deemed dividend	(1,586,050)
Series G Convertible Preferred Stock
Net proceeds	475,000
Derivative warrant liability fair value	(354,535)
Derivative additional investment rights fair value	(285,048)
Other issuance costs (finders' fee)	(40,000)
Make whole payments liability	(135,000)
Deemed dividend	$ (339,583)

Stockholders_ Deficiency (Detai

Stockholders’ Deficiency (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended	12 Months Ended
	Jun. 24, 2015	Jul. 31, 2017	Mar. 27, 2014	Apr. 27, 2017	Jul. 31, 2017	Jul. 31, 2016	Apr. 30, 2017	Mar. 27, 2017	Feb. 28, 2017	Feb. 09, 2017	Jan. 18, 2017
Common stock issued		1,068,101			1,068,101	908,541					53,211
Acquisition in HDS											51.00%
Shares of common stock, obligated to issue											230,000
Common stock purchase warrants, exercise price										$ 7.40
Common stock payable		$ 2,168,951			$ 2,168,951
Warrants, exercise price					$ 15
Total Warrants Outstanding, Value					$ 50,000
Warrants expired during period					65,896
Common shares attributable to conversion of preferred stock		76
Accounts payable and accrued expenses		$ 9,865,484			$ 9,865,484	8,950,870
Amortization of debt discount					$ 131,724
Warrants						$ 383,877
Current exercise price						$ 15
Weighted average exercise price		$ 31.02			$ 31.02	$ 15
Weighted average remaining life						2 years 1 month 6 days
Estimated fair value of warrants						$ 2,048,846
Series G Convertible Preferred Stock
Convertible preferred stock, shares authorized		1,000			1,000	1,000
Convertible preferred stock, cumulative percentage of interest		9.00%			9.00%	9.00%
Convertible preferred stock, par value (in dollars per share)		$ 1,000			$ 1,000	$ 1,000
Convertible preferred stock, shares issued		0			0	500
Convertible preferred stock shares issued value
Common shares attributable to conversion of preferred stock					33,333
Convertible preferred stock conversion price	$ 15
Conversion of stock, amount converted					$ 150
Common stock issued on conversion of preferred stock		43,333			43,333
Issuance costs	$ 25,000
Initial "Make-whole payments"	$ 135,000
Accounts payable and accrued expenses		$ 0			$ 0	$ 135,000
Series F Convertible Preferred Stock
Convertible preferred stock, shares authorized		4,150	4,150		4,150	4,150
Convertible preferred stock, cumulative percentage of interest		9.00%	9.00%		9.00%	9.00%
Convertible preferred stock, par value (in dollars per share)		$ 1,000	$ 1,000		$ 1,000	$ 1,000
Convertible preferred stock, shares issued		0	2,075		0	120
Convertible preferred stock shares issued value
Common shares attributable to conversion of preferred stock					69,167
Convertible preferred stock conversion price			$ 15
Late fee per annum			18.00%
Preferred stock outstanding	55,883		27,942
Aggregate subscription amount, maximum			$ 2,075,000
Conversion of stock, amount converted					$ 2,075
Common stock issued on conversion of preferred stock		97,108			97,108
Initial cash proceeds			2,020,000
Issuance costs			55,000
Initial "Make-whole payments"			$ 560,250
Accounts payable and accrued expenses						$ 32,400
Series I Convertible Preferred Stock
Convertible preferred stock, shares authorized		6,000			6,000	6,000		6,000
Convertible preferred stock, cumulative percentage of interest		9.00%			9.00%	9.00%
Convertible preferred stock, par value (in dollars per share)		$ 0.001			$ 0.001	$ 0.001		$ 1,000
Convertible preferred stock, shares issued		790			790	0
Convertible preferred stock shares issued value		$ 1			$ 1
Convertible preferred stock, conversion terms					The Series H and Series I Convertible Preferred Stock are convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $2.50 per share. An aggregate of 46,000,000 shares of the Company’s common stock would be issuable upon conversion of both the Series H and Series I Preferred Stock if all shares of such preferred stock contemplated by the securities purchase agreement are issued. The Series I Preferred Stock have a special one-time voting rights that provide at the first meeting of the Corporation’s stockholders following the initial issuance of the Preferred Stock, and all adjournments of such meeting, the Preferred Stock shall be entitled to vote on (i) the election of individuals to serve as members of the Board of Directors, and (ii) any proposal to increase the authorized number of shares of Common Stock. The Preferred Stock, as a class, shall be entitled to cast a number of votes on such proposal equal to fifty percent (50%) of the total number of votes entitled to be cast at such meeting (determined as of the record date for such meeting) by all other outstanding shares of the Corporation’s capital stock. Each share of Preferred Stock shall be entitled to cast a number of votes equal to the aggregate number determined pursuant to the last sentence divided by one thousand (1,000).
Series H Convertible Preferred Stock
Convertible preferred stock, shares authorized		109,000			109,000	109,000		109,000
Convertible preferred stock, cumulative percentage of interest		9.00%			9.00%	9.00%
Convertible preferred stock, par value (in dollars per share)		$ 1,000			$ 1,000	$ 0.001		$ 1,000
Convertible preferred stock, shares issued		3,000			3,000	0		3,000
Convertible preferred stock shares issued value		$ 3			$ 3			$ 3,000,000
Convertible preferred stock, conversion terms					The Series H and Series I Convertible Preferred Stock are convertible at the option of the holder at any time into shares of the Company’s common stock at an effective conversion price of $2.50 per share. An aggregate of 46,000,000 shares of the Company’s common stock would be issuable upon conversion of both the Series H and Series I Preferred Stock if all shares of such preferred stock contemplated by the securities purchase agreement are issued.
Common shares attributable to conversion of preferred stock					1,200,000
Salvo
Issue discount				$ 66,560
Salvo | Series I Convertible Preferred Stock
Conversion of stock, amount converted				399
Idebtedness retired				399,363
Moscato
Issue discount				65,164
Moscato | Series I Convertible Preferred Stock
Conversion of stock, amount converted				391
Idebtedness retired				$ 390,984
Shares Issued
Common stock issued		31,195			31,195
Remain To Be Issued
Common stock issued		72,614			72,614
Common stock payable		$ 1,071,851			$ 1,071,851
Series G Convertible Preferred Stock
Common stock issued upon conversion of preferred stock							10,000		33,333
Converted stock amount, payment to holder							$ 150		$ 350
Common stock issued as "make-whole payments" on conversions of preferred stock							4,688		15,294
Convertible preferred stock, shares authorized	1,000
Convertible preferred stock, cumulative percentage of interest	9.00%
Convertible preferred stock, par value (in dollars per share)	$ 1,000
Convertible preferred stock, shares issued	500
Late fee per annum	18.00%
Preferred stock outstanding	138,333
Aggregate subscription amount, maximum	$ 500,000
Initial cash proceeds	$ 475,000
Series F Convertible Preferred Stock
Common stock issued upon conversion of preferred stock							8,000
Converted stock amount, payment to holder							$ 120
Common stock issued as "make-whole payments" on conversions of preferred stock							4,235
Warrant
Common stock issued		103,809			103,809
Warrants Outstanding		0			0
Warrants exercised		3,333			3,333
Warrants issued on cashless basis		314,649			314,649

Derivative Liabilities - Deriva

Derivative Liabilities - Derivative warrant liability (Details) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Notes to Financial Statements
Balance - Derivative warrant liability Value	$ 2,048,846	$ 2,363,415
No. of Warrants - Derivative warrant liability	383,878	512,911
Forfeited or expired, value	$ (240,906)	$ (455,573)
Forfeited or expired, no. of warrants	(65,896)	(129,033)
Warrants exercised, value	$ (1,532,336)
Warrants exercised	(317,982)
Decrease in fair value of derivative warrant liability	$ (275,604)	$ 141,004
Balance - Derivative warrant liability Value		$ 2,048,846
No. of Warrants - Derivative warrant liability		383,878

Derivative Liabilities - Fair v

Derivative Liabilities - Fair value assumptions, derivative warrant liability (Details)	1 Months Ended
	Jul. 31, 2016$ / shares
Notes to Financial Statements
Current exercise price	$ 15
Time to expiration	2 years 1 month 6 days
Risk-free interest rate	0.76%
Estimated volatility	101.00%
Dividend	0.00%
Stock price at period end date	$ 8

Derivative Liabilities - Fair51

Derivative Liabilities - Fair value assumptions, derivative additional investment rights liability (Details)	1 Months Ended
	Jul. 31, 2016$ / sharesshares
Notes to Financial Statements
Underlying number of units of convertible preferred stock | shares	500
Underlying number of units of warrants | shares	33,333
Current exercise price of warrants	$ 15
Current conversion price of preferred stock	$ 15
Time to expiration	18 days
Risk-free interest rate	0.0038
Estimated volatility	0.13
Dividend	0.00%
Stock price at period end date	$ 8

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Derivative warrants weighted average remaining life	1 year 10 months
Recognition of gain (loss)	$ 193,408	$ 50,746
Fair value of derivative liability	0	2,048,846
Additional recognition of gain, “Change in fair value of derivative liabilities”		314,569
Series G Convertible Preferred Stock
Fair value of derivative liability	$ 0	$ 193,408

Common stock options granted, f

Common stock options granted, forfeited or expired and exercised - Stock-Based Compensation (Details 1) - $ / shares	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding, Beginning	19,639	30,233
Options Granted		18,345
Options Forfeited or expired	(1,544)	(3,000)
Options Exercised		(25,939)
Options Outstanding, Ending	18,095	19,639
Options Exercisable	18,095
Weighted Average Exercise Price per Share, Beginning	$ 30	$ 50
Weighted Average Exercise Price per Share, Granted		1
Weighted Average Exercise Price per Share, Forfeited or expired	1	280
Weighted Average Exercise Price per Share, Exercised		1
Weighted Average Exercise Price per Share, Ending	31.02	30
Weighted Average Exercise Price per Share, Exercisable	$ 31.02	$ 15

Information on stock options ou

Information on stock options outstanding - Stock-Based Compensation (Details 2) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Options Outstanding	18,095	19,639	30,233
Weighted Average Exercise Price per Share	$ 31.02	$ 30	$ 50
Options Weighted Average Remaining Life (Years)	1 year 1 month 9 days
Options Aggregate Intrinsic Value	$ 69,843
Exercise Price 1
Options Range of Exercise Price	$ 1
Options Range of Exercise Price	$ 1
Options Outstanding	17,245
Weighted Average Exercise Price per Share	$ 1
Options Weighted Average Remaining Life (Years)	1 year 15 days
Exercise Price 640
Options Range of Exercise Price	$ 640
Options Range of Exercise Price	$ 640
Options Outstanding	850
Weighted Average Exercise Price per Share	$ 640
Options Weighted Average Remaining Life (Years)	2 years 7 months 10 days

Intrinsic value of stock option

Intrinsic value of stock options - Stock-Based Compensation (Details 3) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Aggregate Intrinsic Value of Options Exercised		$ 363,151
Cash Received for Exercise of Stock Options		$ 2,952

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2015
Share-based employee compensation		$ 30,297
Outstanding options	18,095	19,639	30,233
Share based compensation for deferred salary and director fees		18,345
Market value of options	$ 5.05	$ 79
Stock Option Plan 2006
Common stock reserved for future issuance	135,000
Common stock reserved for future awards	64,485
Stock Option Plan 2001
Common stock reserved for future issuance	12,000
Common stock reserved for future awards	4,139
Common Stock
Share-based employee compensation	$ 0	$ 0
Stock Options
Share-based employee compensation	$ 0	$ 30,297
Outstanding options	37,964
Outstanding options, weighted average remaining contractual term	1 year 1 month 9 days
Share based compensation for deferred salary and director fees	15,393
Market value of options	$ 123,417

Acquisition of Hema Diagnosti57

Acquisition of Hema Diagnostics Systems, LLC - Net purchase price of HDS (Details) - USD ($)	6 Months Ended
	Jan. 18, 2017	Jul. 31, 2017	Jul. 31, 2016
Purchase price:
Shares	53,211	1,068,101	908,541
At Closing
Purchase price:
Stock Price at Closing	$ 4.77
Shares	53,191
Fair Value	$ 253,721
After Closing
Purchase price:
Stock Price at Closing	$ 4.77
Shares	20
Fair Value	$ 95
Post Reverse Stock Split
Purchase price:
Stock Price at Closing	$ 4.77
Shares	230,000
Fair Value	$ 1,097,100
Net Purchase Price
Purchase price:
Fair Value	$ 1,350,916

Fair Value Assumptions Used in

Fair Value Assumptions Used in Accounting for Warrants (Details) - $ / shares	1 Months Ended	12 Months Ended
	Jul. 31, 2016	Jul. 31, 2017	Apr. 27, 2017
Exercise price	$ 15
Time to expiration	2 years 1 month 6 days
Risk-free interest rate	0.76%
Estimated volatility	101.00%
Dividend	0.00%
Stock price at period end date	$ 8
Warrant
Exercise price			$ 2.50
Time to expiration		4 years 5 months 20 days
Risk-free interest rate		1.84%
Estimated volatility		122.70%
Dividend		0.00%
Stock price at period end date			$ 5.05

Fair Value Assumptions Used i59

Fair Value Assumptions Used in Accounting for Call Options (Details) - $ / shares	1 Months Ended	12 Months Ended
	Jul. 31, 2016	Jul. 31, 2017
Risk-free interest rate	0.76%
Estimated volatility	101.00%
Remaining Term	2 years 1 month 6 days
Stock price at valuation date	$ 8
Call Option
Risk-free interest rate		1.34%
Estimated volatility		143.90%
Remaining Term		2 years 5 months 20 days
Stock price at valuation date		$ 5.05

Acquisition of Hema Diagnosti60

Acquisition of Hema Diagnostics Systems, LLC - Preliminary purchase price allocation of HDS (Details)	6 Months Ended
	Jan. 18, 2017USD ($)
Business Combinations [Abstract]
Cash and cash equivalents	$ 12,363
Accounts receivable, net	980
Inventory, net	21,141
Other current assets	91,474
Property and equipment, net	4,249
Other assets, net	39,675
Accounts payable and accrued expenses	(489,390)
Loan to related parties	(13,323,391)
Net assets of HDS	(13,642,899)
Non-controlling interest	(1,297,939)
In-Process Research & Development	2,911,377
Goodwill	13,380,377
Total Purchase Price	$ 1,350,916

Acquisition of Hema Diagnosti61

Acquisition of Hema Diagnostics Systems, LLC - Carrying amount of goodwill and other intangible assets (Details)	12 Months Ended
	Jul. 31, 2017USD ($)
Total
Beginning balance
Acquisition of HDS	16,291,754
Current year amortization
Impairment of goodwill	(13,380,377)
Ending balance	2,911,377
Goodwill
Beginning balance
Acquisition of HDS	13,380,377
Current year amortization
Impairment of goodwill	(13,380,377)
Ending balance
Other Intangibles, net
Beginning balance
Acquisition of HDS	2,911,377
Current year amortization
Impairment of goodwill
Ending balance	$ 2,911,377

Acquisition of Hema Diagnosti62

Acquisition of Hema Diagnostics Systems, LLC (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jan. 18, 2017	Jul. 31, 2017	Jul. 31, 2016
Business Combinations [Abstract]
Acquisition of interest	51.00%
Acquisition of outstanding limited liability company units	4,950
Shares exchanged for outstanding limited liability units	53,191
Value of shares exchanged for outstanding limited liability units	$ 253,721
Common stock issued	53,211	1,068,101	908,541
Limited liability company units receied	300
Warrants to be issued		$ 66,060,026
Call Option	$ 13,431,706
Call option recorded as an asset		4,237,829
Changes in fair value of contingent purchase consideration		$ (61,822,197)
Common stock to be issued	230,000
Warrant issued to acquire stock	15,000,000
Common stock, price per year	$ 2.50
Total consideration	$ 1,350,916
Intangible assets acquired	2,911,377
Goodwill acquired	13,400,000
Aggregate purchase price	$ 1

Segment Information (Details)

Segment Information (Details) - USD ($)	Jul. 31, 2017	Jul. 31, 2016
Identifiable Assets	$ 10,094,545	$ 26,274
Canada
Identifiable Assets	2,881,326	25,930
United States
Identifiable Assets	$ 7,213,219	$ 344

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 24, 2017	Jul. 31, 2017
Subsequent Event description	On August 24, 2017, the Company and Core Tech Solutions, Inc. (“Core Tech”) entered into a letter of intent (“LOI”) contemplating Company’s acquisition of a controlling interest of the outstanding capital stock of Core Tech for a total consideration of $15,000,000 in accordance with the terms and conditions therein.
Hema Diagnostic Systems, LLC
Advances		$ 94,000